1. Introduction
The oral microbiota has generally been less explored than the gut microbiota. However, in recent years, there has been a growing interest in research on the oral microbiome [1], becoming one out of five research priorities of the human microbiome project [2]. Research on the gut microbiota has benefited from advanced technologies and increased availability of fecal samples, which have made studies easier and more direct [3]. However, the oral microbiota is equally important in determining both oral and systemic health since it represents the first entry door for nutrients and pathogens in the digestive system [1,4].
The exploration of the oral microbiota is recently growing, thanks in part to the use of advanced sequencing technologies and increasing awareness of the importance of maintaining a balanced microbiota [1]. Research is beginning to elucidate how dietary habits, oral hygiene, and environmental factors can influence the composition and function of the oral microbiota, and how these changes may be linked to oral and systemic diseases [5,6]. In this context, diet plays a pivotal role in shaping both the oral and gut microbiota composition. The variety of dental problems associated with oral dysbiosis alter food choices leading to the consumption of soft and easy-to-chew foods, frequently rich in saturated fats and refined sugars but lacking essential beneficial nutrients (e.g., proteins, fiber, vitamins, and minerals) [7,8,9] with the consequent disruption of gut microbiota homeostasis [10]. Some nutrients, bioactive compounds and dietary patterns as well as certain probiotic and prebiotic strains seem to have beneficial effects on both the oral and gut microbiota. Furthermore, key microbial byproducts and derived bioactive components, such as short-chain fatty acids (SCFAs), trimethylamine N-oxide (TMAO), indole and its derivatives, bile acids, and lipopolysaccharides (LPSs), seem to play central roles in mediating various pathological conditions, by acting on inflammation, oxidative stress, lipid and glucose metabolism, and body barrier integrity. There is growing research interest in the interaction between the oral and the gut microbiota within three main routes of communication namely the enteral, the hematogenous and fecal–oral routes [11]. The aim of this review is therefore to provide an overview of the interactions between oral and gut microbiota, and the influence of diet and related metabolites on this axis.
2. Overview of the Oral and Gut Microbiota Composition Across the Lifespan
The oral microbiota is a complex and dynamic ecosystem composed of a wide range of microorganisms, including bacteria, viruses, fungi, and archaea [12]. The Human Oral Microbiome Database (eHOMD) is one of the most comprehensive databases on oral human microbiota [13]. Figure 1 shows the main relative % phyla of oral microbiota stored in the HOMD.
Bacteria are the predominant components of the oral microbiota and represent a wide variety of species (i.e., over 700) [12]. The oral cavity is composed of both oxygen-deprived areas (e.g., subgingival surfaces) and relatively oxygen-rich areas (e.g., supragingival surfaces), thus supporting both aerobic and anaerobic bacterial species [14]. The main bacterial phyla in the oral microbiota include Bacillota, Actinomycetota, Pseudomonadota, Bacteroidota, and Spirochaetota, with Spirochaetes being the main genus [15]. The phylum Bacillota includes bacteria such as Streptococcus, which are among the most abundant in the oral cavity and are involved in dental plaque and caries formation [16]. Other members include Lactobacillus, which may also be implicated in dental caries formation [17]. Actinomycetota such as Actinomyces spp. and Bifidobacterium spp. play important roles in the balance of oral microbiota [18]. Pseudomonadota including Neisseria are commonly found in the oral mucosa and saliva [19]. Some bacteria in the Bacteroidota group, such as Prevotella spp., are associated with gum disease and periodontal disease [20]. In Spirochaetota, spirochetes such as Treponema are related to advanced periodontal disease and other oral infections [21]. Fungi, especially those belonging to the Candida genus (such as Candida albicans), are present in small amounts in the oral microbiota. However, Candida albicans can become pathogenic, causing infections such as oral candidiasis, especially in immunocompromised individuals [22].
The oral microbiota also hosts a series of viruses, including phages (viruses that infect bacteria). Phages can influence the composition of the oral microbiota by preferring or eventually killing specific bacteria [23]. Additionally, viruses such as the Human Papillomavirus (HPV) may also be present in the oral cavity and have been associated with oral cancer [24]. Although present in smaller amounts than bacteria, Archaea, such as those in the genus Methanobrevibacter, are part of the oral microbiota [25,26]. Some studies suggest that they may play a role in dental plaque formation, periodontitis and bad breath (i.e., halitosis), as some genera of Archaea are implicated in methane production [26,27,28].
It has been reported that oral microbiota composition, once established, remains relatively stable over time [29]. However, several factors across the life course including diet, oral hygiene, and hormonal changes can lead to oral dysbiosis [5]. At birth, the composition of the oral microbiota is mainly influenced by gestational age (i.e., full-term vs. premature), type of delivery (i.e., cesarean section vs. vaginal delivery), whether the infant is breastfed or formula-fed, maternal nutritional status, and exposure to antibiotics [30]. During this period, there is a shift from a relatively simple microbiota to a more complex one as the child grows, begins tooth eruption and starts eating solid food. Indeed, it has been suggested that the establishment of the adult oral microbiota seems to be determined by 18 months of age [31]. Hormonal changes as well as oral hygiene during puberty can also impact the oral microbiota [32]. During the adolescence period, oral bacteria can proliferate, particularly with the rise in saliva production and changes in the pH of the mouth. Teenagers may also have higher levels of gingivitis or dental plaque due to inconsistent oral hygiene practices [33]. In adulthood, the oral microbiota becomes more stable and diverse, influenced by factors like diet, oral hygiene habits, lifestyle choices (e.g., smoking, alcohol consumption), medication use (particularly antibiotics), or underlying pathological conditions (e.g., diabetes, gum disease) [19].
With aging, the diversity of the oral microbiota may decrease [34]. In particular, the number of beneficial bacteria may decline, while the abundance of potentially harmful bacteria can increase, contributing to oral diseases like gum disease, dry mouth, and tooth decay [34]. Oral commensal Neisseria tends to decline with aging (i.e., after the age of 40), while lactobacilli, Streptococcus anginosus and Gemella sanguinis species increase after the age of 60 [35]. Older adults are also more likely to have dentures or other dental appliances, which can further alter the oral microbial community [34]. In fact, notable differences have been found in both the composition and diversity of the oral microbiota, especially between older adults wearing dentures versus those having natural teeth. In denture wearers, bacilli and actinobacteria have been predominantly found at denture and oral mucosa levels [36]. Furthermore, having residual natural teeth significantly impacts oral microbiota composition and diversity of denture wearers [36]. Older people with less natural teeth show predominant commensals such as Prevotella histicola, Veillonella atypica, Streptococcus salivarius and Streptococcus parasanguinis [34,37]. However, it has been reported that toothy centenarians (i.e., those with 20 or more remaining natural teeth, also called ‘successful oral agers’) have a more diverse oral microbiota [38]. In particular, the oral microbiota composition of toothy centenarians is characterized by a predominance of the phyla Spirochaetota and Synergistota, of the genus Aggregatibacter, Prevotella spp., Campylobacter spp., Anaeroglobus spp., Selenomonas spp., and Fusobacterium spp., and of the Porphyromonas endodontalis species, found both in plaque and saliva [38]. A higher relative abundance of genera like Bifidobacterium and Scardovia, and species such as P. gingivalis, T. forsythia, and P. intermedia have been detected only in dental plaque of toothy centenarians [38], while in edentulous centenarians, the microbiota composition seems to be predominated at the phylum level by Bacillota and Actinomycetota, while at the genus level, the composition is predominated by Streptococcus spp. in both dental plaque and saliva [38].
On the other hand, human gut microbiota in adults is mostly composed of Bacteroidota and Bacillota (at least 90% of all phylogenetic types) [39], which is further subdivided to consist of more than 100 distinct bacterial species [40]. It is well known that gut microbiota changes with age. In particular, it dynamically changes from birth until three years of age and then becomes more stable [41,42,43,44]. However, during aging, the microbiota composition seems to change (mainly in the diversity of species) once again [45,46,47,48]. In older adults, a decrease in the ratio of Bacillota/Bacteroidota, a reduced number of bifidobacteria and an increase in certain proteobacteria have been reported [49] (Figure 2).
Interestingly, gut microbiota composition in centenarians has been reported to be more diverse compared to the general older population. In particular, it has been documented that Bacillota still represent a significant proportion of the gut microbiota in centenarians. Among Bacillota, more beneficial species such as Lactobacillus, known for their anti-inflammatory and antioxidant effects, have been reported in Chinese centenarians [52]. In Sardinian centenarians, researchers have reported a depletion of Faecalibacterium prausnitzii and Eubacterium rectale, but enriched Methanobrevibacter smithii and Bifidobacterium adolescentis compared with young and older adults [53]. Regarding Pseudomonadota, an overall slight increase has been reported with enrichment in Escherichia coli [50,53,54]. These changes are not related solely to aging but also to other contributing factors including antibiotic therapy, comorbidities, immune system alterations (e.g., immune senescence), increased intestinal permeability to lipopolysaccharides, and modifications in diet and lifestyle [45,46,55,56,57]. Table 1 compares the main oral and gut microbiota changes across the lifespan.
3. Overview on the Interaction Between Oral and Gut Microbiota
The oral–gut microbiota axis is a relatively new field of research, but it is rapidly gaining interest [58]. Although most studies have focused separately on the oral and gut microbiota, emerging evidence highlighted that the two microbiota are interconnected and may influence each other through various mechanisms [59]. The process of oral colonization has been closely linked to the gut microbiota, being anatomically continuous regions in the gastrointestinal tract [59] and through various cross-talk axes, including the oral/lung/gut axis [60,61]. The oral microbiota plays a crucial role in influencing the lung microbiota, primarily due to the translocation of microorganisms through the “bioaerosol” process, which transports them from the oral cavity to the lower airway tract [60,61]. Consequently, the state of eubiosis in the oral microbiota is strongly related to the lung microbiota, which is in turn connected to the gut microbiota and, by extension, to all the microbiota communication axes [60,61].
A recent human study [62] found the presence of 61 amplicon sequence variants (ASVs) in the 96% of participants considered in both the oral and gut microbiota. Of these, 26 ASVs from 18 genera were found in both children and adults, suggesting these microorganisms are persistent colonizers across different life stages. However, this study [62] also emphasized the presence of age-related changes in the microbial composition between children and adults, indicating that microbial diversity remains almost stable until the age of 45, with significant changes thereafter. Notably, the authors reported that 62% of the shared ASVs were more abundant in the oral cavity, indicating that oral-to-gut translocation is a primary mechanism of microbiota transfer between these habitats [62].
Communication pathways between oral and gut microbiota include the enteral, hematogenous and fecal–oral routes. Figure 3 provides an overview of the main mechanisms of interaction between oral and gut microbiota.
3.1. The Enteral Route
Each day, nearly 1 to 1.5 L of saliva are produced and swallowed in the human gastrointestinal tract [63] along with ingested food [64]. It has been thus suggested that oral bacteria can be ingested and reach the gut (mainly through saliva), where they may colonize and alter the composition of the gut microbiota. However, since gastric acid and alkaline bile can influence the translocation of oral bacteria, there has been a great debate about whether oral microbiota can colonize the gut. Research has indicated that oral bacteria can migrate to the gut in individuals with weakened oral–gut chemical barriers (such as bile and gastric acid), like infants, people with gastrointestinal disease, or using proton-pump inhibitors (PPIs), and older people [59,64,65]. In fact, it has been reported that the presence of oral bacteria in the gut is more common in older adults compared to younger adults [59,62,66,67], with the use of PPIs resulting in low gastric acidity [65], and with the use of antibiotics [68]. Certain periodontal pathogens, such as Porphyromonas gingivalis, Klebsiella spp., Helicobacter pylori, Streptococcus spp., Veillonella spp., Parvimonas micra, and Fusobacterium nucleatum, are capable of surviving in acidic conditions and can thus reach the intestine [11,69]. On the other hand, under normal physiological conditions, some species like Prevotella from saliva, have also been found in human stool samples [70]. Additionally, Helicobacter pylori infection can disturb the oral microbiota balance and further compromise the gastric environment, promoting the growth of oral bacteria like Fusobacterium nucleatum and Porphyromonas gingivalis in the human gut [11,71].
Furthermore, some bacteria can produce biofilms or be enveloped by some layers and substances (e.g., mucus) that can potentially give them protection from harsh environments [58]. Biofilm formation enables pathogens like Streptococcus mutans to survive in the human oral cavity by utilizing mechanisms such as the production of reutericyclin, which suppresses nearby commensal bacteria and contributes to dysbiosis [11,72].
3.2. The Hematogenous Route
Oral bacteria can also spread through the bloodstream to other body sites under certain conditions. Mechanical disruptions like brushing or chewing, inflamed periodontal tissues, or lesions from dental procedures can facilitate the transition of bacteria into the circulatory system through the vascularization and gingival ulceration of periodontal pockets [11,64,73]. Interestingly, some practices such as sleep bruxism (the involuntary grinding or clenching of teeth) can play a role in the migration of oral bacteria in the gut, thus constituting a hypothetical brain–oral–gut axis. In fact, sleep bruxism can lead to oral tissue damage [74], potentially allowing oral bacteria to enter the bloodstream (i.e., oral bacteremia) and then reach the gastrointestinal tract [75]. The presence of oral pathogens can exacerbate inflammation, leading to damage both at oral (i.e., soft and hard periodontal tissues) and at a systemic level [11,64]. As a result, oral bacteria, including Streptococcus, Porphyromonas gingivalis, and Fusobacterium nucleatum, can spread throughout the body, reaching distant organs such as the gut, triggering systemic pro-inflammatory responses and potentially contributing to the pathogenesis of gut diseases [11,64]. In animal models, Fusobacterium nucleatum-induced periodontitis has been shown to alter the bacterial microbiota in the gut, promoting intestinal inflammation [76]. In humans, the hematogenous pathway has been documented as the primary route for Fusobacterium nucleatum to reach colon tumors, in which it has been associated with chemoresistance and poor prognosis [77]. Virulence factors from periodontal pathogens further enhance inflammation and compromise intestinal epithelial barrier, allowing bacteria and metabolites to leak into the bloodstream, thus strengthening microbial cross-talks throughout the body [11]. The presence of pro-inflammatory oral bacteria, such as Porphyromonas gingivalis, in the bloodstream could also affect the gut microbiota, worsening gut permeability, endotoxemia, and leading to metabolic dysregulation and gut dysbiosis, predisposing the body to a vicious cycle of systemic inflammation that damages both microbiomes in both mice models and in humans [63,78,79]. In particular, Porphyromonas gingivalis disrupts the colonic epithelial barrier by producing gingipains, which act as mucus-detaching proteases, and by degrading tight junction proteins [64].
Streptococcus salivarius, an early colonizer of the oral cavity, can also inhabit the intestinal tract, where it down-regulates the nuclear transcription factor-κB (NF-κB) in small intestinal epithelial cells, contributing to both intestinal inflammation and homeostasis [1].
Augmented levels of some oral bacteria including Streptococcus mutans (cariogenic), Porphyromonas gingivalis and Fusobacterium nucleatum (the main pathogens associated with periodontal disease) have been found in the gut of patients with IBD, Human Immunodeficiency Virus (HIV) infection, liver cirrhosis, and colon cancer [63,64,80,81,82,83]. An elevated presence of Campylobacter concisus and Fusobacterium nucleatum has also been detected in fecal samples and intestinal biopsies of IBD patients [84] and in human colorectal cancer [85,86]. Furthermore, in IBD, bile acid malabsorption and reduced expression of bile acid receptors have been suggested to facilitate the translocation of oral pathobionts from the oral cavity to the gut [87,88]. Several mechanisms through which oral bacteria can contribute to IBD have been proposed: (1) Porphyromonas gingivalis and Klebsiella pneumoniae can reduce the expression of tight junction protein-1 and occludin, leading to damage of the intestinal epithelial barrier; (2) Fusobacterium nucleatum and Klebsiella pneumoniae can stimulate the production of the pro-inflammatory lipopolysaccharide; (3) Fusobacterium nucleatum and Candida albicans can disrupt T helper (Th)1/Th17 cell balance, leading to inflammatory responses disrupting the host immune system and immune escape induction; (4) Klebsiella pneumoniae and Fusobacterium nucleatum can migrate to the gut, triggering inflammasome activation in immune cells, which promotes intestinal inflammation [63].
Antibiotics have long been associated with alterations in gut microbiota composition [89]. However, antibiotics are frequently used in dentistry for prophylaxis, to treat infections, and to prevent systemic bacteremia [90]. This, in turn, highlights the importance of communication between the oral and gut microbiota via the bloodstream. Recently, the American Dentistry Association [91] recommended that antibiotic prophylaxis may be indicated before dental procedures only in certain patient subpopulations (e.g., patients with underlying cardiac conditions) and to follow the American Heart Association guidelines for infective endocarditis prophylaxis [92]. Some concerns have been raised regarding antimicrobial resistance, which is accelerating, especially in older adults, being responsible for an increased risk of adverse outcomes and death [93,94]. Inappropriate antibiotic use, as well as poor infection prevention strategies and decreased vaccination rates, have been identified as the main reasons for the global increase in antimicrobial resistance [93]. Indeed, the expert panel of the American Dental Association Council on Scientific Affairs and the Center for Evidence-Based Dentistry suggested antibiotic treatment for target conditions when systemic involvement is present, and prioritization of immediate conservative dental treatment in all cases [95]. In this regard, probiotic supplementation is frequently used as adjunct therapy to prevent antibiotic-induced dysbiosis [96]. Some evidence has formerly documented that certain probiotics can help reducing both occurrence and duration of antibiotic-associated diarrhoea, including the prevention of Clostridioides difficile-associated diarrhoea [97]. However, current research does not support the idea that probiotics can fully restore the microbiota to its state before antibiotic use, with limited studies showing that a specific probiotic preparation might delay the recovery of the microbiota after antibiotic disruption [97]. According to a recent systematic review and meta-analysis, probiotic supplementation during antibiotic treatment was not found to be influential on low-diversity dysbiosis [96].
3.3. Fecal-Oral Route
Translocation of microorganisms from the gut to the oral cavity can also take place through fecal–oral transmission, either through direct contact or indirectly via contaminated food and beverages. Hands play a crucial role as carriers, facilitating the transfer of fecal and oral microorganisms both within households and between individuals [11,98] as its microbiota overlaps with that of the mouth and the gut [98]. Fecal–oral route transmission is a significant concern, particularly in areas with limited access to clean water, poor sanitation, and hygiene [59]. Immunocompromised individuals and people undergoing radiation therapy for head and neck cancer are also more susceptible to infections through fecal–oral transmission [59]. In particular, radiation therapy has in turn been associated with oral dysbiosis, characterized by increased colonization of opportunistic pathogens such as staphylococci, Candida spp., and species from the Enterobacteriaceae family, even worsening within poor oral hygiene [99,100].
Additionally, the fecal–oral route facilitates human-to-human pathogen transmission. Enteric viruses, like hepatitis A and E, easily spread via the fecal–oral route in unsanitary conditions and across people, and can significantly disrupt the gut microbiota balance [101,102,103,104]. Helicobacter pylori, associated with severe gastrointestinal diseases, can also spread via this route and has been related to hepatitis A infection [105].
3.4. Metabolite-Mediated Interactions Between Oral and Gut Microbiota
Recent evidence suggests that metabolites produced by the oral microbiota can influence the gut microbiota and vice versa, although their interplay seems to be quite complex [106]. Key microbial byproducts and derivatives, as well as bioactive components, such as SCFAs, TMAO, indole and its derivates, bile acids, and LPS, appear to play central roles in mediating various pathological conditions, by acting on inflammation, oxidative stress, lipid and glucose metabolism, and body barrier integrity.
SCFAs in the gut may be translocated through the bloodstream to the oral cavity [106]. In turn, the oral microbiota might send signals back to the gut, influencing digestive health. This could indicate that the oral and gut microbiota interact through metabolites to maintain or not the microbial balance. The SCFAs acetate, propionate, and butyrate are produced by gut microbiota starting from undigested dietary fiber [106,107]. The SCFAs that remain unmetabolized in the gut can be circulated to other organs, including the oral cavity in which they can influence pH, through the hepatic portal vein [108]. SCFAs can also be produced by the oral microbiota from carbohydrate hydrolysis or amino acid metabolism [106], although their production in the oral cavity is generally lower compared to the gut [109,110]. These metabolites have anti-inflammatory properties and can influence oral and systemic health in several ways. SCFAs can exert a direct influence on neutrophils by (1) decreasing their production of reactive oxygen species (ROS) and myeloperoxidase and (2) enhancing their apoptosis [106]. In the gut, some amino acids like arginine can be metabolized to compounds like nitric oxide (NO) influencing oral microbiota health through antibacterial function [111]. However, SCFAs seem to play a more complex role in the oral cavity. In fact, although SCFAs are generally produced by oral microbiota as a part of normal local metabolic processes, their overproduction at the oral level has been indicated as a marker of oral dysbiosis, triggering soft tissue damage and an increased inflammatory response in the oral cavity [106,112]. On the contrary, a higher amount of SCFAs in the gut does not damage intestinal epithelium cells, probably because of a better adaptive capacity of the gut mucosa compared to the oral mucosa [106]. At the systemic level, SCFAs have been suggested to exert metabolic effects on obesity and glucose homeostasis [113,114]. SCFAs regulate both metabolism and immune function of the liver mainly by inhibiting histone deacetylases or through the activation of G-protein coupling receptors (GPCRs) [115]. A metagenome-wide association study reported a lower abundance of several butyrate-producing bacteria in fecal samples from patients with type 2 diabetes (T2D) compared with healthy controls, suggesting a potential beneficial effect of butyrate in metabolic diseases [116]. However, there is a paucity of information on its exact role since some studies found a higher amount of butyrate in stool samples of overweight and obese people than in those with a normal weight and a similar diet [117,118,119]. It should also be considered that fecal levels of butyrate might not reflect its physiological concentrations since less than 10% of butyrate produced is excreted with feces [120]. In mice, butyrate seems to improve insulin sensitivity, increase energy expenditure, and promote mitochondrial functioning [121]. Butyrate, by serving as a histone deacetylase inhibitor and ligand to GPCRs, affects cellular signaling in target cells like enteroendocrine cells [122,123]. Indeed, recent evidence indicated butyrate as a new therapeutic target for obesity-related metabolic disorders including T2D [113,122]. Proposed treatment strategies, aimed at increasing its intestinal levels, include supplementation of butyrate-producing bacteria, such as Faecalibacterium prausnitzii, and dietary fiber, as well as fecal microbiota transplantation [113,122]. SCFAs also seem to affect lipid metabolism by influencing various pathways in the liver, adipose tissue, and muscle [124,125]. Acetate and butyrate participate in lipogenesis in the liver, where they can stimulate adenosine monophosphate-activated protein kinase (AMPK) phosphorylation and activity, increasing fatty acid oxidation and glycogen storage [124]. On the other hand, propionate most clearly acts as an inhibitor of hepatic lipogenesis by blocking fatty acid synthase expression [124]. Additionally, both acetate and propionate can inhibit intracellular lipolysis, while propionate may also enhance the lipid-buffering capacity in the adipose tissue by increasing the activity of lipoprotein lipase for triglyceride extraction, finally resulting in a reduced lipid overflow and a decreased ectopic fat accumulation, with positive effects on insulin sensitivity [124]. Given their role in regulating inflammation, glucose and lipid metabolism, SCFAs emerged as promising metabolites regulating the pathological process of metabolic dysfunction-associated steatotic liver disease (MASLD) [11,115]. However, the role of SCFAs in regulating lipid metabolism needs further investigation [123,124].
Inflammation, particularly when chronic and of low grade, acts as a key mediator in the impact of oral pathogens on both local and systemic health. Pathogens from the oral cavity can invade the body and elicit immune responses that produce pro-inflammatory cytokines such as tumor necrosis factor alfa (TNF-α), interleukin-1 beta (IL-1β), and IL-6 [126]. These cytokines further exacerbate inflammation in other body sites, leading to vascular damage, endothelial injury, and the formation of atherosclerotic plaques, which can elevate the risk of cardiovascular diseases [126]. In this context, LPSs are important components of the outer membrane of Gram-negative bacteria, found in both the oral and intestinal microbiota, with significant pro-inflammatory effects [115]. LPS are potent activators of the innate immune system. In particular, LPSs bind to Toll-like receptor 4 (TLR4) on immune cells (e.g., macrophages, dendritic cells), activating an intracellular signaling cascade that induces the production of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6) and chemokines from Kupffer cells [115]. This last mechanism seems also to be triggered by the translocation of P. gingivalis, including its LPS, from the oral cavity to the gut, thus leading to increased inflammation and gut dysbiosis [11]. When P. gingivalis colonizes the gut, it compromises intestinal barrier function and markedly raises endotoxemia levels by increasing LPS in the bloodstream. The elevation of LPS in the circulation in turn stimulates the expression of flavin-containing monooxygenase 3 (FMO3) and elevates circulating TMAO levels, finally leading to metabolic imbalance, dysbiosis, and inflammation [78,79]. P. gingivalis also reduces the expression of tight junction proteins, such as cytosolic zonula occludens-1 (ZO-1) and occludin, in the small intestine, thus enhancing intestinal permeability [78]. Additionally, LPS from P. gingivalis stimulate both the NF-κB pathway and Caspase-1 inflammasome, increasing IL-1β and IL-18 production [127], which in turn drive both intestinal inflammation and, by crossing the blood–brain barrier, promote neuroinflammation by activating microglia [128]. P. gingivalis also appears to stimulate IL-6 expression via the janus kinase 2/glycogen synthase kinase 3 beta/signal transducer and activator of transcription 3 (JAK2/GSK3-β/STAT3) signaling pathway, which is linked to carcinogenesis and the development of oral squamous cell carcinoma [127].
Furthermore, inflammation may promote mitochondrial dysfunction, leading to the release of mitochondrial damage-associated molecular patterns. This, in turn, triggers increased production of cytokines, chemokines, NO, and ROS, which further exacerbate mitochondrial damage, creating a vicious cycle [129]. This is particularly evident in the older population, in which oral diseases may contribute to chronic systemic inflammation, associated with increased morbidity and mortality [126]. Periodontal pathogens like Fusobacterium nucleatum contribute to inflammation by releasing toxic factors, which not only damage the local tissues but also facilitate the progression of diseases like colorectal cancer [126]. Periodontal disease and IBD are both chronic inflammatory diseases, probably interacting through the oral–gut axis. P. gingivalis, when it reaches the gut, alters microbiota, promoting inflammation through its interaction with oral-derived Th17 cells transferred to the gut, exacerbating colitis via immune activation and increased levels of IL-1β [130], with subsequent damage to the mucosal barrier [131]. Of note, it has been documented that nearly 10–30% of IBD patients may present oral symptoms both before, during or after gastrointestinal manifestations [132]. This suggests a bidirectional relationship between oral and gut microbiota disruptions in IBD and periodontal disease with consequent inflammatory responses both at the intestinal and at the oral level [132]. Furthermore, oxidative stress in conditions like periodontitis may further trigger inflammatory responses as the levels of salivary oxidants such as malondialdehyde and NO were found to be higher in periodontitis patients [133]. In turn, NO has significant implications for human health, particularly in cardiometabolic diseases such as atherosclerosis as a critical signaling molecule [134]. Being synthesized by endothelial cells, NO may induce relaxation of vascular smooth muscle, therefore leading to the dilatation of blood vessels [134], as well as the inhibition of smooth muscle cell proliferation, platelet aggregation and oxidative stress, with its deficiency being associated with the atherosclerotic process [134]. Oral microbiota, at least to a certain extent, can stimulate the production of NO. In particular, salivary glands absorb nearly 25% of nitrate in food, which is also formed by endogenous oxidation [134]. At the oral level, symbiotic bacteria generate nitrate reductase, metabolizing nitrate (i.e., NO3−) found in saliva into nitrite (i.e., NO2−) [135]. This is the first crucial step in the process of NO conversion in the human body [135]. Subsequently, nitrite can be further reduced to NO [136,137]. Oral genera like Rothia and Neisseria are known to support vascular function and blood pressure regulation through this nitrate-nitrite–nitric oxide pathway, while genera like Prevotella and Veillonella seem to impair NO homeostasis [138]. Trimethylamine is produced by the gut microbiota through catabolism of dietary choline, phosphatidylcholine, betaine, and carnitine [139]. Once produced, TMA enters the liver via the portal vein and is oxidized to TMAO by FMO3 [139]. In the human body, TMAO influences multiple metabolic pathways, such as cholesterol metabolism, oxidative stress, immune system regulation, and inflammation, being thus proposed as a novel biomarker of metabolic syndrome [115,134,140]. TMAO can inhibit the synthesis of bile acids, which are crucial for cholesterol elimination, and also disrupt the process of reverse cholesterol transport, leading to the accumulation of cholesterol within macrophages and contributing to the formation of foam cells, a key feature of atherosclerotic plaques [141,142]. As a gut microbiota-derived metabolite, TMAO indirectly promotes atherosclerosis-related inflammation by stimulating ROS and activating signaling pathways involving AMPK and sirtuin 1 [143]. In mice, TMAO also worsens oxidative stress by reducing superoxide dismutase levels, increasing malondialdehyde and glutathione peroxidase levels, and triggering the production of proinflammatory cytokines [144]. Additionally, TMAO amplifies angiotensin II-induced vasoconstriction in mice, further connecting the oral–gut axis to hypertension in both mice and humans [145]. In this context, mice models suggest the oral pathogen P. gingivalis can significantly increase levels of endotoxemia through enhancing LPS concentration in the bloodstream, which in turn stimulate FMO3 expression and raise plasma TMAO levels, leading to gut dysbiosis and inflammation, further highlighting the oral–gut communication [79]. For instance, dental treatments to restore oral function in older adults could unintentionally lead to bacteremia, worsening systemic inflammation instead of counteracting it [146]. This highlights the complex role inflammation plays, acting as both a local response to infection and a widespread factor influencing overall health.
Bile acid alterations may also represent a common pathway influencing oral, esophageal and gut microbiota. The identification of several new bile acid receptors and signaling pathways made bile acids a crucial group of metabolites with diverse functions in regulating various aspects of human health, especially for microbiota balance and the mucosal immune system within the intestine [147]. Consequently, disturbances in bile acid metabolism or circulation have been associated with intestinal disorders, including IBD and colon cancer [147]. Physiologically, bile acids favor the digestion of dietary fats by forming micelles, promoting nutrient absorption [148]. Bile acids, mainly through the farnesoid X receptor (FXR), widely expressed in the ileum and the liver, also regulate gene expression in diverse metabolic pathways, including lipid and glucose metabolism, as well as bile acid synthesis itself [115,149,150]. The FXR also mediates anti-inflammatory effects and maintains intestinal barrier integrity. In particular, the FXR, through the down-regulation of the expression of liver X receptor and sterol regulatory element-binding protein 1c seems to reduce fatty acid and triglyceride synthesis in the liver [151]. The modulation of FXR signaling in the gut has thus been suggested as a potential target strategy for both prevention and treatment of the fatty liver and metabolic alterations [152]. Regarding glucose metabolism, it has been reported that mice lacking FXR exhibit both decreased glucose tolerance and insulin sensitivity [149]. Activating FXR with cholic acid seems to reduce glucose levels by suppressing the expression of several liver genes involved in gluconeogenesis [149]. The downregulation of phosphoenolpyruvate carboxykinase expression mediated by the small heterodimer partner highlights the important role of FXR in regulating glucose metabolism [153].
Beyond FXR, Takeda G protein-coupled receptor 5 (TGR5), also known as G protein-coupled bile acid receptor, stimulates glucagon-like peptide-1 (GLP-1) secretion, affecting energy and glucose metabolism, insulin sensitivity and inflammation [154,155]. In particular, the TGR5 modulates inflammatory response via NF-κB signaling pathway and cytokines release (e.g., IL-1β, IL-6, and TNF-α) from macrophages [155,156]. Secondary bile acids at high concentrations have been reported to damage epithelial cells and promote IBD and carcinogenic processes, especially in the colon, through mechanisms like oxidative stress, DNA damage, and resistance to apoptosis [156,157].
Under particular pathophysiological conditions like duodeno-gastro-esophageal reflux, bile acid reflux into the stomach and esophagus can occur, negatively impacting the esophageal epithelium [148]. In gastroesophageal reflux disease (GERD), gastric and duodenal fluids are repeatedly exposed to the esophagus, leading to heartburn and regurgitation [158]. Bile acids, when protonated at acidic pH, have a synergistic damaging effect with gastric acid [159,160]. Saliva may reflect esophageal exposure to bile acids, and their presence is common in conditions like GERD and Barrett’s esophagus [148,161]. Due to their role in Barrett’s esophagus, bile acids have been proposed as diagnostic markers of this condition [148]. Additionally, bile acid alterations influence gut microbiota composition and function, contributing to inflammation and susceptibility to opportunistic infections [162,163]. Elevated bile acid levels may also promote tumor activity in the gastrointestinal epithelium [164]. Bile reflux into the esophagus can damage local mucosa in gastroduodenal disorders [161,164], and high levels of bile acids can activate inflammatory signaling pathways, leading to chronic inflammation in the intestine and colon epithelium [164]. Bile acids have been implicated in the pathogenesis of colorectal and liver cancer, with high-fat Western diets and microbial activity as contributing factors [165]. Primary bile acids are produced by the liver, while gut microbes modify these compounds, enhancing their diversity and biological functions [166]. The microbial metabolism of bile acids regulates both microbial diversity and host physiology, suggesting a bidirectional relationship [166]. At the oral level, recent studies reported an increased total salivary bile acid concentration in GERD patients [148,167]. Krause et al. [167] found higher levels of conjugated salivary bile acids such as glycocholic acid, glycodeoxycholic acid and glycochenodeoxycholic acid in GERD patients, which have been identified as potentially tumorigenic [168]. Other studies also found taurocholic acid in the saliva of GERD patients [148,161], but only glycocholic acid has been associated with dental erosion in this population [161]. An acidic oral environment, as in the case of dental erosion involving the loss of tooth enamel, stimulates protein enzyme production and alters microbial composition, favoring the growth of acid-tolerant bacteria [169,170,171]. This shift can lead to dysbiosis, reducing beneficial bacteria and increasing harmful bacteria linked to caries and periodontitis [169,172,173]. A bidirectional relationship between bile acids and oral microbiota dysbiosis may thus be postulated, as dysbiosis has been associated with GERD [174], Barrett’s esophagus [175], and esophageal cancer [176]. Microbiota alterations in GERD and Barrett’s esophagus, such as an increased abundance of Gram-negative bacteria (e.g., Fusobacterium, Neisseria, Campylobacter, Bacteroides, Proteobacteria, Veillonella) and decreased Gram-positive Streptococcus, may thus result from bile and gastric acid reflux [177]. In turn, oral bacteria also play a role in shaping the microbiota of the gallbladder and upper gastrointestinal tract with associations to gallstone disease (GSD) pathogenesis, although the exact mechanisms have not been fully elucidated [178]. Pseudomonadota, Bacillota, Bacteroidota, Actinomycetota, Fusobacteriota, and Synergistota have been found in the bile of GSD patients [179]. Of these, Pyramidobacter genus, belonging to the phylum of Synergistota and mainly found in the oral cavity, has been found in the bile of GSD patients, further suggesting a role of oral microbiota in gallbladder disease [179]. Poor oral hygiene and missing teeth have been associated with GSD [180], thus suggesting a potential vicious circle among bile acids, dental erosion, oral bacteria and cholelithiasis.
Indole and its derivatives are bacterial metabolites of tryptophan and act as quorum-sensing molecules, regulating bacterial activities like biofilm formation, motility, and virulence [181]. This regulation helps maintain balanced microbial communities in both the oral cavity and gut [181,182]. In fact, the presence of both Gram-positive and Gram-negative bacteria like Escherichia coli, Fusobacterium nucleatum, Klebsiella, Shigella dysenteriae, Vibrio cholerae and Enterococcus faecalis, as well as Porphyromonas gingivalis, producing indole in both the oral cavity and the gut, suggests that indole signaling could influence microbial stability and potentially impact overall health [181,182,183]. Indole and its derivatives regulate epithelial barrier integrity, immune responses, and gastrointestinal motility via intestinal receptors [184]. These compounds also enter the liver through the bloodstream, where they influence liver inflammation as well as glucose and lipid metabolism [184]. While indole’s role in the oral cavity is less extensively studied, higher concentrations of indole have been detected in the saliva and gingival crevicular fluid of patients suffering from periodontitis, suggesting indole metabolites produced by oral pathogens might contribute to oral dysbiosis and host inflammation [182]. Indole presence could potentially influence the stability or dispersal of oral biofilms, or modulate the behavior of other oral microbes [181,182,183]. The majority of indole compounds exert their biological effects by activating three primary receptor-mediated signaling pathways: the aryl hydrocarbon receptor (AhR), pregnane X receptor (PXR), and TLR4, which are expressed in various gut cell types, including epithelial cells, fibroblasts, and immune cells [185] and that regulate the expression of genes involved in immunity, inflammation, and intestinal barrier function [115]. Indole plays a protective role in the gut by strengthening epithelial tight junctions and reducing inflammation and tissue injury [115]. It also modulates GLP-1 secretion in colonic L cells, enhancing calcium influx and slowing GLP-1 breakdown [186]. Key indole derivatives include the indole-3-aldehyde (IAld), Indole-3-acetic acid (IAA) and Indole-3-propionic acid (IPA) [115]. The IAld produced from indole pyruvate by aromatic amino acid aminotransferase acts as a ligand for the AhR. It stimulates IL-22 production, protecting against mucosal damage and candidiasis [187]. IAld also promotes IL-10 receptor expression, supporting anti-inflammatory pathways [188]. Levels of IAA are reduced in individuals with metabolic syndrome and obesity, correlating with glucose intolerance and liver steatosis [115,189]. IAA decreases pro-inflammatory cytokines like TNF-α, monocyte chemoattractant protein-1, and IL-1β, reduces free fatty acid synthesis, and inhibits lipogenesis in an AhR-dependent manner, suggesting a protective role against MASLD [190]. As a PXR ligand, IPA suppresses intestinal inflammation and enhances gut barrier function [191]. It also acts as an antioxidant, protecting brain, neuronal, and liver cells from oxidative damage [115]. Recent findings show IPA improves glucose metabolism by lowering blood glucose and insulin levels in rats, indicating new potential targets for insulin resistance [192].
In this context, autoinducer 2 (AI-2) is a universal signaling molecule produced by many bacterial species, including oral bacteria like A. naeslundii and S. oralis, S. mutans, P. gingivalis, and F. nucleatum [193,194,195], that facilitates interspecies communication and coordinates biofilm formation, virulence, and motility [183,195]. AI-2-promoted coaggregation and biofilm maturation have been suggested as key mechanisms for dental plaque development, contributing to dental caries and periodontal diseases [193]. Indole and AI-2 can regulate overlapping bacterial functions but often have opposite effects. To date, in some bacteria, AI-2 promotes biofilm formation, while indole inhibits it [183]. This interplay helps fine-tune microbial community structure and behavior [183].
The balance between AI-2 and indole could therefore influence the overall structure and pathogenicity of both the oral and gut microbiota, by influencing the transition from commensal to pathogenic states in bacteria, affecting diseases in the oral cavity and gut.
4. Dietary Strategies
Diet plays a significant role in the modulation of both oral [196,197] and gut microbiota [198,199]. Fermentable carbohydrates, such as simple sugars and starches, serve as primary energy sources for bacterial metabolism [200]. Indeed, diets rich in carbohydrates, particularly in refined sugars, contribute to increased dental plaque accumulation exacerbating the proliferation of cariogenic bacteria like S. mutans and F. nucleatum [201,202]. Westernized diets characterized by refined grains and ultra-processed foods and low in fruits and vegetables, and thus poor in micronutrients, predispose the body to a greater pro-inflammatory state both at the periodontal tissue [9] and systemic level [203]. Although the association between carbohydrate intake and periodontal disease is less well studied [204], emerging evidence suggests that dietary patterns emphasizing whole grains over refined carbohydrates may confer periodontal benefits [73,205,206]. Certain nutrients, including dietary fats and vitamin C, appear to support Fusobacteria, while dietary fiber and dairy products have been associated with oral microbial homeostasis [6,207,208,209,210]. Dietary fiber is a key component of healthy dietary patterns, including the Mediterranean diet [211]. As previously mentioned, dietary fiber is metabolized by the gut microbiota into SCFAs, which serve as an energy source for colon cells, help maintain gut barrier integrity, and regulate inflammation. This anti-inflammatory effect can positively impact oral health by reducing periodontal inflammation, while also influencing overall metabolism and immune function [206,212]. Diets low in fiber and high in ultra-processed foods can often lead to the alteration of intestinal barrier integrity and increased gut permeability, allowing the translocation of harmful bacterial products, such as oral pathogens (e.g., F. nucleatum, P. gingivalis) and LPS, to spread through the bloodstream, triggering low-grade systemic inflammation [128,213,214]. Increasing fiber intake has been shown to enhance butyrate-producing gut bacteria and to decrease Alloprevotella at the oral level, highlighting the positive effects of healthy dietary patterns on both oral and gut health [215]. Evidence from preclinical studies also suggests that food additives, despite their impact being difficult to identify within dietary questionnaires, can negatively affect gut homeostasis [211]. In particular, the most widely studied are emulsifiers, which have been associated with a decreased bacterial diversity, an increased amount of pro-inflammatory bacteria such as E. coli, as well as with altered microbial gene regulation, decreased mucus thickness, increased gut permeability and activated inflammatory pathways [211]. Dietary fiber also promotes a balanced salivary flow, which helps maintain a stable oral pH, as well as microbial transfer and diversity [11,80,216]. Saliva contains antimicrobial proteins [11,216] and helps the natural cleaning processes of the oral cavity [128]. In fact, a decreased salivary flow can predispose the body to increased colonization by acidogenic and pathogenic bacteria (e.g., Streptococcus and Fusobacterium genera), further exacerbating pro-inflammatory responses with the abnormal release of IL-6, IL-8, IL-17, IL, 23, IL-1β, TNF-α [216]. Plant-based diets, rich in fibers, vitamins, minerals, and bioactive compounds, play a crucial role in promoting oral and gut health by fostering beneficial microbial communities. These diets support the growth of oral Streptococci such as Streptococcus sanguinis, S. gordonii, and S. salivarius, which are among the earliest colonizers of the oral cavity [217]. Epidemiological evidence indicates that consuming fruits, vegetables, and whole grains significantly lowers the risk of colorectal cancer, largely due to their fiber content, antioxidants, and other bioactive elements such as polyphenols that inhibit cancer cell proliferation and induce apoptosis [218,219,220,221,222]. Plant-based dietary components contribute to a balanced gut microbiota by promoting microbial SCFA production, reducing mucosal inflammation, strengthening the epithelial barrier, and modulating immune responses, thereby supporting immune tolerance and overall gut health [223]. In terms of oral health, plant-based diets have been linked to reduced risk of periodontitis compared to omnivorous diets, likely due to their higher fiber content and lower levels of pro-inflammatory saturated fats, alongside increased polyunsaturated fatty acids (PUFAs) [210,224,225]. This suggests that such diets may enhance the oral–gut–brain axis by promoting healthier microbial communities and reducing inflammation. However, it is worth noting that vegan diets might also pose increased risks for dental erosion and caries, possibly due to lower calcium and vitamin B12 intake and reduced saliva pH [226].
Omega-3 PUFAs are increasingly recognized for their role in modulating both oral and gut microbiota, with important effects on inflammation and oxidative stress. Through their derivatives, the so-called specialized pro-resolving mediators (SPMs), omega-3 PUFAs help resolve inflammation and reduce mitochondrial ROS, supporting tissue health in the oral cavity and gut [227,228,229]. SPMs, produced from dietary omega-3 intake, are present in body fluids such as saliva and gingival tissues, where they interact with immune cells to regulate inflammation in periodontal tissues and promote a healthier balance of oral bacteria [228]. Additionally, in vitro studies suggest direct antibacterial effects of omega-3 PUFAs, inhibiting harmful oral microbes including S. mutans and P. gingivalis [230,231]. In humans, a randomized trial showed that omega-3 fish oil supplementation during periodontal treatment reduced key periodontal pathogens in advanced periodontitis patients [232]. In the gut, omega-3 PUFAs help maintain microbial balance by supporting the production of SCFAs and modulating inflammation, influencing the ratio of dominant bacterial groups (Bacillota/Bacteroidota), which is critical for gut health [229,233]. However, an imbalance between omega-3 and omega-6 intake can disrupt this ratio, potentially contributing to obesity and fatty liver disease [233]. Notably, some long-term human studies have found that omega-3 supplementation does not always produce significant improvements in gut inflammation or cardiovascular outcomes, suggesting effects may depend on factors like dose, duration, and individual health status [227,229].
Excessive alcohol intake has been shown to disrupt both the gut and oral microbiota balance, promoting an overgrowth of Gram-positive species like S. mutans while suppressing taxa such as Fusobacteria at the oral level [207,234].
Beyond beneficial effects on gut microbiota, growing interest surrounds the use of probiotics and prebiotics to support oral microbiota health [197]. Probiotics, defined as live microorganisms that confer health benefits when administered in adequate amounts, have been extensively studied for their role in oral and periodontal health [235]. Prebiotics are selectively fermentable compounds that promote the growth or activity of beneficial microorganisms [236], often working synergistically with probiotics to enhance their efficacy. While the effects of probiotics on periodontal disease have been widely investigated, the role of prebiotics remains underexplored [217,237].
Prebiotics are typically composed of carbohydrate-based compounds such as fructo-oligosaccharides and galacto-oligosaccharides, but can also include non-carbohydrate substances like polyphenols and PUFAs [236]. These compounds selectively stimulate beneficial taxa such as Lactobacilli and Bifidobacteria, while inhibiting pathogens like Clostridia and E. coli [217,236]. Both probiotics and prebiotics exhibit anti-inflammatory and immunomodulatory properties [217,235,236].
Probiotic strains such as Lactobacilli and Bifidobacteria can help maintain microbial eubiosis, modulate immune responses, and produce antimicrobial agents [238,239]. They exert their effects by competing for epithelial adhesion sites, synthesizing bacteriocins, enhancing immune mechanisms such as secretory immunoglobulin A production, and downregulating pro-inflammatory cytokines and matrix metalloproteinases. These actions contribute to the inhibition of pathogenic bacterial growth and modulation of immune responses both locally and systemically [238,239].
Polyphenols, naturally abundant in fruits, vegetables, and whole grains, are bioactive compounds known for their multifaceted health benefits [218]. Although approximately 90–95% of dietary polyphenols evade absorption in the small intestine due to their large molecular size, they still exert significant biological effects, particularly within the oral cavity and gut microbiota [240,241]. One of the most recognized roles of dietary polyphenols is their antioxidant activity: by scavenging free radicals, they help mitigate oxidative stress [240]. Polyphenol metabolism begins in the oral cavity, where despite incomplete knowledge of the exact metabolic pathways, these compounds modulate the host’s inflammatory response [241,242]. Their chemopreventive potential is demonstrated through the modulation of carcinogenesis processes, notably in colorectal cancer prevention [243,244]. This effect is partly attributed to their antimicrobial activity against oral pathogens such as Fusobacterium nucleatum and Porphyromonas gingivalis, inhibiting bacterial growth, adhesion to oral cells, and virulence-associated enzymatic activities [241,245,246,247].
Polyphenols positively influence gut health mainly through (1) their prebiotic effect by promoting the growth of beneficial gut bacteria and enhancing the production of SCFAs and (2) their antimicrobial effect including the suppression of pathogenic bacteria by disrupting their structural and functional integrity. This includes the inhibition of penicillin-binding proteins, leading to weakened peptidoglycan cross-linking and increased lysine content. Additionally, polyphenols create an acidic microenvironment via proton donation, impairment of proton pumps, and depletion of bacterial H+-ATPase activity [248].
5. Conclusions and Future Perspectives
In conclusion, the interaction between the oral and gut microbiota is a complex and evolving area of research that underscores the interdependence of microbial communities across various body sites. Emerging evidence suggests that the oral and gut microbiota influence each other through several mechanisms, including the translocation of microorganisms via saliva, the fecal-oral route and the bloodstream. Disruptions in oral and/or gut microbiota, such as those caused by oral diseases, antibiotics, or gastrointestinal conditions, can lead to dysbiosis, which in turn may contribute to increased systemic inflammation and a range of pathological conditions, including cardiovascular conditions, IBD, and cancer. Some microbiota-produced metabolites and bioactive compounds, including SCFAs, TMAO, indole and its derivates, bile acids, and LPSs appear to play central roles in mediating various pathological conditions, by acting on both microbiota and influencing inflammation, oxidative stress, lipid and glucose metabolism, and body barrier integrity. Interestingly, some nutrients, bioactive compounds and dietary patterns as well as certain probiotic and prebiotic strains seem to have beneficial effects on both the oral and gut microbiota. However, research on the oral–gut microbiota axis is often limited by observational and cross-sectional study designs, small human sample sizes, and the use of animal models that may not accurately reflect human complexity, factors that collectively hinder the generalizability and interpretation of results. As research continues to uncover the nuances of these microbial interactions, understanding the bidirectional relationship between the oral and gut microbiota is crucial for developing strategies to promote overall health and for disease prevention. Examining combined signaling pathways, molecular mechanisms, and microbial metabolites may offer a more comprehensive understanding of how the oral and gut microbiota influence human health.
Conceptualization, D.A. and M.C.-S.; Methodology, D.A. and M.C.-S.; Resources, T.L.; Writing—Original Draft Preparation, D.A. and M.C.-S.; Writing—Review and Editing, D.A., M.C.-S., L.S., M.C., A.F., L.T., R.C.C.-P., F.G.-G., T.L. and P.C.P.; Supervision, D.A., M.C.-S., L.S., L.T., T.L., F.G.-G. and P.C.P.; Funding Acquisition, D.A., M.C.-S., L.T. and T.L. Supervision, D.A., M.C.-S., L.S., L.T., T.L., F.G.-G. and P.C.P. All authors have read and agreed to the published version of the manuscript.
The authors declare no conflicts of interest.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Figure 1 The main relative phyla of oral microbiota. Modified from Santacroce et al. [
Figure 2 Main gut microbiota changes across the lifespan. Based on concepts and findings of Haran and McCormick [
Figure 3 Overview of the three main mechanisms of communication between oral and gut microbiota. (1) Enteral Route: Oral bacteria, such as Porphyromonas gingivalis and Fusobacterium nucleatum, can reach the gut through saliva, particularly in individuals with weakened oral–gut barriers (e.g., older people, those using PPIs). Bile acids also influence oral, esophageal, and gut microbiota, especially in conditions like gastroesophageal reflux disease and Barrett’s esophagus. Oral bacteria, such as Pyramidobacter, also play a role in shaping the microbiota of the gallbladder and upper gastrointestinal tract with associations to gallstone disease pathogenesis. (2) Hematogenous Route: Oral bacteria can enter the bloodstream through disruptions like infections, periodontal disease, dental procedures, or sleep bruxism. This may lead to systemic inflammation and contribute to diseases like IBD and colorectal cancer. Bacteria like Fusobacterium nucleatum and Porphyromonas gingivalis have been linked to gut inflammation and cancer progression. (3) Fecal–Oral Route: Microorganisms can be transmitted from the gut to the oral cavity through contaminated food, water, or direct contact, especially in areas with poor sanitation or among immunocompromised individuals. This route is associated with the spread of pathogens like hepatitis A, Helicobacter pylori, and enteric viruses, disrupting the gut microbiota. ↑: Abundance; ↓: depletion; IBD: inflammatory bowel disease; PPIs: proton pump inhibitors.
Oral and gut microbiota changes across lifespan.
| Infancy (0–2 years) | ||
|---|---|---|
| Oral Microbiota | Gut Microbiota | |
| Main composition | Streptococcus, Staphylococcus, Neisseria | Enterobacteriaceae, Bifidobacterium, Lactobacillus |
| Characteristics and influencing factors | Aerobes dominate; Low diversity; Influenced by delivery mode (i.e., cesarean section vs. vaginal delivery), gestational age (i.e., full-term vs. premature), type of feeding (i.e., breastfeeding vs. formula feeding), maternal nutritional status, exposure to antibiotics. | Early facultative anaerobes; Influenced by maternal microbiota, delivery mode (i.e., vaginal delivery vs. cesarean section), type of feeding (i.e., breastfeeding vs. formula feeding), exposure to antibiotics. |
| Childhood (2–12 years) | ||
| Oral Microbiota | Gut Microbiota | |
| Main composition | Streptococcus, Veillonella, Actinomyces, Fusobacterium | Bacillota (e.g., Clostridium), Bacteroidota, Prevotella |
| Characteristics and influencing factors | Diversity increases; Anaerobes appear with tooth eruption; Influenced by diet (especially high simple sugar intake, solid food), dental problems, infections and oral hygiene. | Transition to adult-like microbiota; Influenced by diet (especially high consumption of processed foods, sugar, and fats), gastrointestinal diseases, infections and antibiotics. |
| Adolescence (13–18 years) | ||
| Oral Microbiota | Gut Microbiota | |
| Main composition | Streptococcus, Fusobacterium, Neisseria, Prevotella | Bacillota, Bacteroidota, Actinobacteria |
| Characteristics and influencing factors | Oral microbiota stabilizes; resembles adult profile; Influenced by hormonal changes, oral hygiene, diet (especially higher in sugars, processed foods, and acidic beverages), use of orthodontic appliances, gingival inflammation (puberty gingivitis), smoking, antibiotic use. | Bacillota/Bacteroidota ratio continues to shift with growth/puberty; Influenced by hormonal changes, diet (high consumption of processed foods, sugary snacks and beverages, alcohol), obesity, smoking, infections, use of antibiotics and hormonal contraceptives. |
| Adulthood (18–65 years) | ||
| Oral Microbiota | Gut Microbiota | |
| Main composition | Streptococcus, Veillonella, Actinomyces, Prevotella, Haemophilus | Firmicutes (e.g., Clostridia), Bacteroidetes, Actinobacteria, Proteobacteria |
| Characteristics and influencing factors | High diversity and relative stability; Influenced by oral hygiene, sleep bruxism, diet (rich in refined sugars and alcohol), pregnancy, smoking, chronic diseases, medications, xerostomia, infections, gingivitis, antibiotics. | Stable core microbiome; Influenced by diet (high in processed foods, sugar, alcohol, and low in fiber), obesity, smoking, infections, chronic diseases, medications, antibiotics. |
| Older People (>65 years) | ||
| Oral Microbiota | Gut Microbiota | |
| Main composition | ↑ Lactobacillaceae, Streptococcus anginosus, and Gemella sanguinis | ↓ Bacillota/Bacteroidota ratio, Bifidobacteriaceae |
| Main composition | Denture users: ↑ Bacillota and Actinomycetota | - |
| Main composition | Edentulous: ↑Prevotella histicola, Veillonella atypica, Streptococcus salivarius, and Streptococcus parasanguinis | - |
| Characteristics and influencing factors | Decreased diversity; Influenced by denture use, xerostomia, dental problems, oral hygiene, diet (softer, more processed foods with higher sugar and fat content), immune senescence, inflamm-ageing, infections, chronic diseases, polypharmacy, medications, antibiotics. | Decreased diversity; Influenced by diet (less fiber and more processed or soft foods due to chewing difficulties or appetite changes), changes in gut motility, reduced digestive secretions, and altered gut barrier function, micronutrient deficiencies, immune senescence, inflamm-ageing, infections, chronic diseases, polypharmacy, antibiotics. |
| Centenarians (100+ years) | ||
| Oral Microbiota | Gut Microbiota | |
| Main composition | Toothy centenarians | ↑ Pseudomonadota (Escherichia coli et rel., Haemophilus spp., Klebsiella pneumoniae et rel., Leminorella spp., Proteus et rel., Pseudomonas, Serratia spp., Vibrio spp., and Yersinia et rel.), Bacillota (Bacillus spp., Staphylococcus spp.) |
| Dental plaque and saliva: ↑ Spirochaetota and Synergistota (at phylum level), Aggregatibacter spp., Prevotella spp., Campylobacter spp., Anaeroglobus spp., Selenomonas spp., Fusobacterium spp., and Porphyromonas endodontalis (at genus level) | ||
| Dental plaque: ↑ Bifidobacterium and Scardovia (at genus level), Porphyromonas gingivalis, Tannerella forsythia, and Prevotella intermedia (at species level) | ||
| Edentulous | ||
| Dental plaque and saliva: ↑ Bacillota and Actinomycetota (at phylum level), Streptococcus spp. (at genus level) | ||
| Characteristics and influencing factors | Toothy centenarians show a more diverse microbiota compared to older adults; Influenced by oral hygiene throughout life, tooth loss, denture use, diets rich in fiber, low in refined sugars and fermented products, immune senescence, inflamm-ageing, chronic disease, medications, antibiotics. | More diverse compared to older adults; reduced Bacillota/Bacteroidota ratio compared to older adults Influenced by genetics, long-term dietary habits, diets rich in fiber, plant-based foods, and fermented products, immune senescence, inflamm-ageing, chronic disease, medications, antibiotics. |
↑ Abundance; ↓ depletion.
1. Peng, X.; Cheng, L.; You, Y.; Tang, C.; Ren, B.; Li, Y.; Xu, X.; Zhou, X. Oral microbiota in human systematic diseases. Int. J. Oral Sci.; 2022; 14, 14. [DOI: https://dx.doi.org/10.1038/s41368-022-00163-7]
2. Turnbaugh, P.J.; Ley, R.E.; Hamady, M.; Fraser-Liggett, C.M.; Knight, R.; Gordon, J.I. The Human Microbiome Project. Nature; 2007; 449, pp. 804-810. [DOI: https://dx.doi.org/10.1038/nature06244]
3. Arnold, J.W.; Roach, J.; Azcarate-Peril, M.A. Emerging Technologies for Gut Microbiome Research. Trends Microbiol.; 2016; 24, pp. 887-901. [DOI: https://dx.doi.org/10.1016/j.tim.2016.06.008]
4. Jia, G.; Zhi, A.; Lai, P.F.H.; Wang, G.; Xia, Y.; Xiong, Z.; Zhang, H.; Che, N.; Ai, L. The oral microbiota—A mechanistic role for systemic diseases. Br. Dent. J.; 2018; 224, pp. 447-455. [DOI: https://dx.doi.org/10.1038/sj.bdj.2018.217]
5. Santacroce, L.; Passarelli, P.C.; Azzolino, D.; Bottalico, L.; Charitos, I.A.; Cazzolla, A.P.; Colella, M.; Topi, S.; Godoy, F.G.; D’Addona, A. Oral microbiota in human health and disease: A perspective. Exp. Biol. Med.; 2023; 248, pp. 1288-1301. [DOI: https://dx.doi.org/10.1177/15353702231187645]
6. Li, X.; Liu, Y.; Yang, X.; Li, C.; Song, Z. The Oral Microbiota: Community Composition, Influencing Factors, Pathogenesis, and Interventions. Front. Microbiol.; 2022; 13, 895537. [DOI: https://dx.doi.org/10.3389/fmicb.2022.895537]
7. Hung, H.-C.; Colditz, G.; Joshipura, K.J. The association between tooth loss and the self-reported intake of selected CVD-related nutrients and foods among US women. Community Dent. Oral Epidemiol.; 2005; 33, pp. 167-173. [DOI: https://dx.doi.org/10.1111/j.1600-0528.2005.00200.x]
8. Gil-Montoya, J.A.; Ferreira de Mello, A.L.; Barrios, R.; Gonzalez-Moles, M.A.; Bravo, M. Oral health in the elderly patient and its impact on general well-being: A nonsystematic review. Clin. Interv. Aging; 2015; 10, pp. 461-467. [DOI: https://dx.doi.org/10.2147/CIA.S54630]
9. O’Connor, J.-L.P.; Milledge, K.L.; O’Leary, F.; Cumming, R.; Eberhard, J.; Hirani, V. Poor dietary intake of nutrients and food groups are associated with increased risk of periodontal disease among community-dwelling older adults: A systematic literature review. Nutr. Rev.; 2020; 78, pp. 175-188. [DOI: https://dx.doi.org/10.1093/nutrit/nuz035]
10. Casati, M.; Ferri, E.; Azzolino, D.; Cesari, M.; Arosio, B. Gut microbiota and physical frailty through the mediation of sarcopenia. Exp. Gerontol.; 2019; 124, 110639. [DOI: https://dx.doi.org/10.1016/j.exger.2019.110639]
11. Xu, Q.; Wang, W.; Li, Y.; Cui, J.; Zhu, M.; Liu, Y.; Liu, Y. The oral-gut microbiota axis: A link in cardiometabolic diseases. Npj Biofilms Microbiomes; 2025; 11, 11. [DOI: https://dx.doi.org/10.1038/s41522-025-00646-5]
12. Sultan, A.S.; Kong, E.F.; Rizk, A.M.; Jabra-Rizk, M.A. The oral microbiome: A Lesson in coexistence. PLoS Pathog.; 2018; 14, e1006719. [DOI: https://dx.doi.org/10.1371/journal.ppat.1006719]
13. HOMD: Human Oral Microbiome Database. Available online: https://www.homd.org/ (accessed on 24 January 2023).
14. Kuramitsu, H.K.; He, X.; Lux, R.; Anderson, M.H.; Shi, W. Interspecies interactions within oral microbial communities. Microbiol. Mol. Biol. Rev.; 2007; 71, pp. 653-670. [DOI: https://dx.doi.org/10.1128/MMBR.00024-07]
15. Dewhirst, F.E.; Chen, T.; Izard, J.; Paster, B.J.; Tanner, A.C.R.; Yu, W.-H.; Lakshmanan, A.; Wade, W.G. The human oral microbiome. J. Bacteriol.; 2010; 192, pp. 5002-5017. [DOI: https://dx.doi.org/10.1128/JB.00542-10]
16. Lemos, J.A.; Palmer, S.R.; Zeng, L.; Wen, Z.T.; Kajfasz, J.K.; Freires, I.A.; Abranches, J.; Brady, L.J. The Biology of Streptococcus mutans. Microbiol. Spectr.; 2019; 7, pp. 1-18. [DOI: https://dx.doi.org/10.1128/microbiolspec.GPP3-0051-2018]
17. Zhang, Y.; Wang, X.; Li, H.; Ni, C.; Du, Z.; Yan, F. Human oral microbiota and its modulation for oral health. Biomed. Pharmacother.; 2018; 99, pp. 883-893. [DOI: https://dx.doi.org/10.1016/j.biopha.2018.01.146]
18. Wu, C. Human Microbiome, Actinobacteria in. Encyclopedia of Metagenomics; Nelson, K.E. Springer: New York, NY, USA, 2013; pp. 1-7. ISBN 978-1-4614-6418-1
19. Aas, J.A.; Paster, B.J.; Stokes, L.N.; Olsen, I.; Dewhirst, F.E. Defining the normal bacterial flora of the oral cavity. J. Clin. Microbiol.; 2005; 43, pp. 5721-5732. [DOI: https://dx.doi.org/10.1128/JCM.43.11.5721-5732.2005]
20. Sharma, G.; Garg, N.; Hasan, S.; Shirodkar, S. Prevotella: An insight into its characteristics and associated virulence factors. Microb. Pathog.; 2022; 169, 105673. [DOI: https://dx.doi.org/10.1016/j.micpath.2022.105673]
21. Dashper, S.G.; Seers, C.A.; Tan, K.H.; Reynolds, E.C. Virulence Factors of the Oral Spirochete Treponema denticola. J. Dent. Res.; 2011; 90, pp. 691-703. [DOI: https://dx.doi.org/10.1177/0022034510385242]
22. Sztukowska, M.N.; Dutton, L.C.; Delaney, C.; Ramsdale, M.; Ramage, G.; Jenkinson, H.F.; Nobbs, A.H.; Lamont, R.J. Community Development between Porphyromonas gingivalis and Candida albicans Mediated by InlJ and Als3. MBio; 2018; 9, e00202-18. [DOI: https://dx.doi.org/10.1128/mBio.00202-18]
23. Chen, X.; Zou, T.; Ding, G.; Jiang, S. Findings and methodologies in oral phageome research: A systematic review. J. Oral Microbiol.; 2024; 16, 2417099. [DOI: https://dx.doi.org/10.1080/20002297.2024.2417099] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/39420944]
24. Santacroce, L.; Di Cosola, M.; Bottalico, L.; Topi, S.; Charitos, I.A.; Ballini, A.; Inchingolo, F.; Cazzolla, A.P.; Dipalma, G. Focus on HPV Infection and the Molecular Mechanisms of Oral Carcinogenesis. Viruses; 2021; 13, 559. [DOI: https://dx.doi.org/10.3390/v13040559] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33810374]
25. Santacroce, L.; Sardaro, N.; Topi, S.; Pettini, F.; Bottalico, L.; Cantore, S.; Cascella, G.; Del Prete, R.; Dipalma, G.; Inchingolo, F. The pivotal role of oral microbiota in health and disease. J. Biol. Regul. Homeost. Agents; 2020; 34, pp. 733-737. [DOI: https://dx.doi.org/10.23812/20-127-L-45] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32492992]
26. Poehlein, A.; Seedorf, H. Draft Genome Sequences of Methanobrevibacter curvatus DSM11111, Methanobrevibacter cuticularis DSM11139, Methanobrevibacter filiformis DSM11501, and Methanobrevibacter oralis DSM7256. Genome Announc.; 2016; 4, e00617-16. [DOI: https://dx.doi.org/10.1128/genomeA.00617-16]
27. Huynh, H.T.T.; Nkamga, V.D.; Drancourt, M.; Aboudharam, G. Genetic variants of dental plaque Methanobrevibacter oralis. Eur. J. Clin. Microbiol. Infect. Dis.; 2015; 34, pp. 1097-1101. [DOI: https://dx.doi.org/10.1007/s10096-015-2325-x]
28. Bringuier, A.; Khelaifia, S.; Richet, H.; Aboudharam, G.; Drancourt, M. Real-Time PCR Quantification of Methanobrevibacter oralis in Periodontitis. J. Clin. Microbiol.; 2013; 51, pp. 993-994. [DOI: https://dx.doi.org/10.1128/JCM.02863-12]
29. Eriksen, C.; Boustedt, K.; Sonne, S.B.; Dahlgren, J.; Kristiansen, K.; Twetman, S.; Brix, S.; Roswall, J. Early life factors and oral microbial signatures define the risk of caries in a Swedish cohort of preschool children. Sci. Rep.; 2024; 14, 8463. [DOI: https://dx.doi.org/10.1038/s41598-024-59126-z]
30. Agostoni, C.; Kim, K.S. Nutrition and the microbiome 2015. Pediatr. Res.; 2015; 77, pp. 113-114. [DOI: https://dx.doi.org/10.1038/pr.2014.195]
31. Kageyama, S.; Takeshita, T. Development and establishment of oral microbiota in early life. J. Oral Biosci.; 2024; 66, pp. 300-303. [DOI: https://dx.doi.org/10.1016/j.job.2024.05.001]
32. AlHarbi, S.G.; Almushayt, A.S.; Bamashmous, S.; Abujamel, T.S.; Bamashmous, N.O. The oral microbiome of children in health and disease—A literature review. Front. Oral Health; 2024; 5, 1477004. [DOI: https://dx.doi.org/10.3389/froh.2024.1477004]
33. Veenman, F.; van Dijk, A.; Arredondo, A.; Medina-Gomez, C.; Wolvius, E.; Rivadeneira, F.; Àlvarez, G.; Blanc, V.; Kragt, L. Oral microbiota of adolescents with dental caries: A systematic review. Arch. Oral Biol.; 2024; 161, 105933. [DOI: https://dx.doi.org/10.1016/j.archoralbio.2024.105933] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/38447351]
34. Sarafidou, K.; Alexakou, E.; Talioti, E.; Bakopoulou, A.; Anastassiadou, V. The oral microbiome in older adults—A state-of-the-art review. Arch. Gerontol. Geriatr. Plus; 2024; 1, 100061. [DOI: https://dx.doi.org/10.1016/j.aggp.2024.100061]
35. Kazarina, A.; Kuzmicka, J.; Bortkevica, S.; Zayakin, P.; Kimsis, J.; Igumnova, V.; Sadovska, D.; Freimane, L.; Kivrane, A.; Namina, A.
36. O’Donnell, L.E.; Robertson, D.; Nile, C.J.; Cross, L.J.; Riggio, M.; Sherriff, A.; Bradshaw, D.; Lambert, M.; Malcolm, J.; Buijs, M.J.
37. Asakawa, M.; Takeshita, T.; Furuta, M.; Kageyama, S.; Takeuchi, K.; Hata, J.; Ninomiya, T.; Yamashita, Y. Tongue Microbiota and Oral Health Status in Community-Dwelling Elderly Adults. mSphere; 2018; 3, e00332-18. [DOI: https://dx.doi.org/10.1128/mSphere.00332-18]
38. Sekundo, C.; Langowski, E.; Wolff, D.; Boutin, S.; Frese, C. Maintaining oral health for a hundred years and more?—An analysis of microbial and salivary factors in a cohort of centenarians. J. Oral Microbiol.; 2022; 14, 2059891. [DOI: https://dx.doi.org/10.1080/20002297.2022.2059891]
39. Eckburg, P.B.; Bik, E.M.; Bernstein, C.N.; Purdom, E.; Dethlefsen, L.; Sargent, M.; Gill, S.R.; Nelson, K.E.; Relman, D.A. Diversity of the human intestinal microbial flora. Science; 2005; 308, pp. 1635-1638. [DOI: https://dx.doi.org/10.1126/science.1110591]
40. Rajilić-Stojanović, M.; de Vos, W.M. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol. Rev.; 2014; 38, pp. 996-1047. [DOI: https://dx.doi.org/10.1111/1574-6976.12075]
41. Yatsunenko, T.; Rey, F.E.; Manary, M.J.; Trehan, I.; Dominguez-Bello, M.G.; Contreras, M.; Magris, M.; Hidalgo, G.; Baldassano, R.N.; Anokhin, A.P.
42. Hill, C.J.; Lynch, D.B.; Murphy, K.; Ulaszewska, M.; Jeffery, I.B.; O’Shea, C.A.; Watkins, C.; Dempsey, E.; Mattivi, F.; Tuohy, K.
43. The Human Microbiome Project Consortium Huttenhower, C.; Gevers, D.; Knight, R.; Abubucker, S.; Badger, J.H.; Chinwalla, A.T.; Creasy, H.H.; Earl, A.M.; FitzGerald, M.G.
44. Greenhalgh, K.; Meyer, K.M.; Aagaard, K.M.; Wilmes, P. The human gut microbiome in health: Establishment and resilience of microbiota over a lifetime. Environ. Microbiol.; 2016; 18, pp. 2103-2116. [DOI: https://dx.doi.org/10.1111/1462-2920.13318] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27059297]
45. Biagi, E.; Candela, M.; Fairweather-Tait, S.; Franceschi, C.; Brigidi, P. Aging of the human metaorganism: The microbial counterpart. Age; 2012; 34, pp. 247-267. [DOI: https://dx.doi.org/10.1007/s11357-011-9217-5]
46. Claesson, M.J.; Jeffery, I.B.; Conde, S.; Power, S.E.; O’Connor, E.M.; Cusack, S.; Harris, H.M.B.; Coakley, M.; Lakshminarayanan, B.; O’Sullivan, O.
47. Langille, M.G.; Meehan, C.J.; Koenig, J.E.; Dhanani, A.S.; Rose, R.A.; Howlett, S.E.; Beiko, R.G. Microbial shifts in the aging mouse gut. Microbiome; 2014; 2, 50. [DOI: https://dx.doi.org/10.1186/s40168-014-0050-9]
48. Rampelli, S.; Candela, M.; Turroni, S.; Biagi, E.; Collino, S.; Franceschi, C.; O’Toole, P.W.; Brigidi, P. Functional metagenomic profiling of intestinal microbiome in extreme ageing. Aging; 2013; 5, pp. 902-912. [DOI: https://dx.doi.org/10.18632/aging.100623] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24334635]
49. Haran, J.P.; McCormick, B.A. Aging, Frailty, and the Microbiome—How Dysbiosis Influences Human Aging and Disease. Gastroenterology; 2021; 160, pp. 507-523. [DOI: https://dx.doi.org/10.1053/j.gastro.2020.09.060]
50. Biagi, E.; Nylund, L.; Candela, M.; Ostan, R.; Bucci, L.; Pini, E.; Nikkïla, J.; Monti, D.; Satokari, R.; Franceschi, C.
51. Monira, S.; Nakamura, S.; Gotoh, K.; Izutsu, K.; Watanabe, H.; Alam, N.H.; Endtz, H.P.; Cravioto, A.; Ali, S.I.; Nakaya, T.
52. Wu, L.; Xie, X.; Li, Y.; Liang, T.; Zhong, H.; Yang, L.; Xi, Y.; Zhang, J.; Ding, Y.; Wu, Q. Gut microbiota as an antioxidant system in centenarians associated with high antioxidant activities of gut-resident Lactobacillus. npj Biofilms Microbiomes; 2022; 8, 102. [DOI: https://dx.doi.org/10.1038/s41522-022-00366-0]
53. Wu, L.; Zeng, T.; Zinellu, A.; Rubino, S.; Kelvin, D.J.; Carru, C. A Cross-Sectional Study of Compositional and Functional Profiles of Gut Microbiota in Sardinian Centenarians. mSystems; 2019; 4, e00325-19. [DOI: https://dx.doi.org/10.1128/mSystems.00325-19]
54. Wang, F.; Yu, T.; Huang, G.; Cai, D.; Liang, X.; Su, H.; Zhu, Z.; Li, D.; Yang, Y.; Shen, P.
55. Candela, M.; Biagi, E.; Brigidi, P.; O’Toole, P.W.; De Vos, W.M. Maintenance of a healthy trajectory of the intestinal microbiome during aging: A dietary approach. Mech. Ageing Dev.; 2014; 136–137, pp. 70-75. [DOI: https://dx.doi.org/10.1016/j.mad.2013.12.004] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24373997]
56. Pérez-Cobas, A.E.; Gosalbes, M.J.; Friedrichs, A.; Knecht, H.; Artacho, A.; Eismann, K.; Otto, W.; Rojo, D.; Bargiela, R.; von Bergen, M.
57. Woodmansey, E.J.; McMurdo, M.E.T.; Macfarlane, G.T.; Macfarlane, S. Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects. Appl. Environ. Microbiol.; 2004; 70, pp. 6113-6122. [DOI: https://dx.doi.org/10.1128/AEM.70.10.6113-6122.2004]
58. Tan, X.; Wang, Y.; Gong, T. The interplay between oral microbiota, gut microbiota and systematic diseases. J. Oral Microbiol.; 2023; 15, 2213112. [DOI: https://dx.doi.org/10.1080/20002297.2023.2213112]
59. Park, S.-Y.; Hwang, B.-O.; Lim, M.; Ok, S.-H.; Lee, S.-K.; Chun, K.-S.; Park, K.-K.; Hu, Y.; Chung, W.-Y.; Song, N.-Y. Oral-Gut Microbiome Axis in Gastrointestinal Disease and Cancer. Cancers; 2021; 13, 2124. [DOI: https://dx.doi.org/10.3390/cancers13092124]
60. Mammen, M.J.; Scannapieco, F.A.; Sethi, S. Oral-lung microbiome interactions in lung diseases. Periodontol. 2000; 2020; 83, pp. 234-241. [DOI: https://dx.doi.org/10.1111/prd.12301]
61. Santacroce, L.; Man, A.; Charitos, I.A.; Haxhirexha, K.; Topi, S. Current knowledge about the connection between health status and gut microbiota from birth to elderly. A narrative review. Front. Biosci.; 2021; 26, pp. 135-148. [DOI: https://dx.doi.org/10.52586/4930]
62. Costa, C.F.F.A.; Correia-de-Sá, T.; Araujo, R.; Barbosa, F.; Burnet, P.W.J.; Ferreira-Gomes, J.; Sampaio-Maia, B. The oral-gut microbiota relationship in healthy humans: Identifying shared bacteria between environments and age groups. Front. Microbiol.; 2024; 15, 1475159. [DOI: https://dx.doi.org/10.3389/fmicb.2024.1475159]
63. Wang, A.; Zhai, Z.; Ding, Y.; Wei, J.; Wei, Z.; Cao, H. The oral-gut microbiome axis in inflammatory bowel disease: From inside to insight. Front. Immunol.; 2024; 15, 1430001. [DOI: https://dx.doi.org/10.3389/fimmu.2024.1430001]
64. Kunath, B.J.; De Rudder, C.; Laczny, C.C.; Letellier, E.; Wilmes, P. The oral-gut microbiome axis in health and disease. Nat. Rev. Microbiol.; 2024; 22, pp. 791-805. [DOI: https://dx.doi.org/10.1038/s41579-024-01075-5]
65. Imhann, F.; Bonder, M.J.; Vich Vila, A.; Fu, J.; Mujagic, Z.; Vork, L.; Tigchelaar, E.F.; Jankipersadsing, S.A.; Cenit, M.C.; Harmsen, H.J.M.
66. Iwauchi, M.; Horigome, A.; Ishikawa, K.; Mikuni, A.; Nakano, M.; Xiao, J.-Z.; Odamaki, T.; Hironaka, S. Relationship between oral and gut microbiota in elderly people. Immun. Inflamm. Dis.; 2019; 7, pp. 229-236. [DOI: https://dx.doi.org/10.1002/iid3.266] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31305026]
67. Odamaki, T.; Kato, K.; Sugahara, H.; Hashikura, N.; Takahashi, S.; Xiao, J.-Z.; Abe, F.; Osawa, R. Age-related changes in gut microbiota composition from newborn to centenarian: A cross-sectional study. BMC Microbiol.; 2016; 16, 90. [DOI: https://dx.doi.org/10.1186/s12866-016-0708-5] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27220822]
68. Kitamoto, S.; Nagao-Kitamoto, H.; Hein, R.; Schmidt, T.M.; Kamada, N. The Bacterial Connection between the Oral Cavity and the Gut Diseases. J. Dent. Res.; 2020; 99, pp. 1021-1029. [DOI: https://dx.doi.org/10.1177/0022034520924633] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32464078]
69. Mukherjee, S.; Chopra, A.; Karmakar, S.; Bhat, S.G. Periodontitis increases the risk of gastrointestinal dysfunction: An update on the plausible pathogenic molecular mechanisms. Crit. Rev. Microbiol.; 2025; 51, pp. 187-217. [DOI: https://dx.doi.org/10.1080/1040841X.2024.2339260]
70. Könönen, E.; Gursoy, U.K. Oral Prevotella Species and Their Connection to Events of Clinical Relevance in Gastrointestinal and Respiratory Tracts. Front. Microbiol.; 2021; 12, 798763. [DOI: https://dx.doi.org/10.3389/fmicb.2021.798763]
71. Chen, X.; Wang, N.; Wang, J.; Liao, B.; Cheng, L.; Ren, B. The interactions between oral-gut axis microbiota and Helicobacter pylori. Front. Cell. Infect. Microbiol.; 2022; 12, 914418. [DOI: https://dx.doi.org/10.3389/fcimb.2022.914418]
72. Tang, X.; Kudo, Y.; Baker, J.L.; LaBonte, S.; Jordan, P.A.; McKinnie, S.M.K.; Guo, J.; Huan, T.; Moore, B.S.; Edlund, A. Cariogenic Streptococcus mutans Produces Tetramic Acid Strain-Specific Antibiotics That Impair Commensal Colonization. ACS Infect. Dis.; 2020; 6, pp. 563-571. [DOI: https://dx.doi.org/10.1021/acsinfecdis.9b00365]
73. De Angelis, P.; Gasparini, G.; Manicone, P.F.; Passarelli, P.C.; Azzolino, D.; Rella, E.; De Rosa, G.; Papi, P.; Pompa, G.; De Angelis, S.
74. Thayer, M.L.T.; Ali, R. The dental demolition derby: Bruxism and its impact-part 1: Background. Br. Dent. J.; 2022; 232, pp. 515-521. [DOI: https://dx.doi.org/10.1038/s41415-022-4143-8] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35459823]
75. Thomas, C.; Minty, M.; Vinel, A.; Canceill, T.; Loubières, P.; Burcelin, R.; Kaddech, M.; Blasco-Baque, V.; Laurencin-Dalicieux, S. Oral Microbiota: A Major Player in the Diagnosis of Systemic Diseases. Diagnostics; 2021; 11, 1376. [DOI: https://dx.doi.org/10.3390/diagnostics11081376] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34441309]
76. Haraga, H.; Sato, T.; Watanabe, K.; Hamada, N.; Tani-Ishii, N. Effect of the Progression of Fusobacterium nucleatum-induced Apical Periodontitis on the Gut Microbiota. J. Endod.; 2022; 48, pp. 1038-1045. [DOI: https://dx.doi.org/10.1016/j.joen.2022.04.014] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35545147]
77. Abed, J.; Maalouf, N.; Manson, A.L.; Earl, A.M.; Parhi, L.; Emgård, J.E.M.; Klutstein, M.; Tayeb, S.; Almogy, G.; Atlan, K.A.
78. Arimatsu, K.; Yamada, H.; Miyazawa, H.; Minagawa, T.; Nakajima, M.; Ryder, M.I.; Gotoh, K.; Motooka, D.; Nakamura, S.; Iida, T.
79. Xiao, L.; Huang, L.; Zhou, X.; Zhao, D.; Wang, Y.; Min, H.; Song, S.; Sun, W.; Gao, Q.; Hu, Q.
80. Sedghi, L.; DiMassa, V.; Harrington, A.; Lynch, S.V.; Kapila, Y.L. The oral microbiome: Role of key organisms and complex networks in oral health and disease. Periodontol. 2000; 2021; 87, pp. 107-131. [DOI: https://dx.doi.org/10.1111/prd.12393]
81. Atarashi, K.; Suda, W.; Luo, C.; Kawaguchi, T.; Motoo, I.; Narushima, S.; Kiguchi, Y.; Yasuma, K.; Watanabe, E.; Tanoue, T.
82. Fang, Y.; Chen, X.; Chu, C.H.; Yu, O.Y.; He, J.; Li, M. Roles of Streptococcus mutans in human health: Beyond dental caries. Front. Microbiol.; 2024; 15, 1503657. [DOI: https://dx.doi.org/10.3389/fmicb.2024.1503657]
83. Han, Y.; Wang, B.; Gao, H.; He, C.; Hua, R.; Liang, C.; Xin, S.; Wang, Y.; Xu, J. Insight into the Relationship between Oral Microbiota and the Inflammatory Bowel Disease. Microorganisms; 2022; 10, 1868. [DOI: https://dx.doi.org/10.3390/microorganisms10091868] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36144470]
84. Strauss, J.; Kaplan, G.G.; Beck, P.L.; Rioux, K.; Panaccione, R.; Devinney, R.; Lynch, T.; Allen-Vercoe, E. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm. Bowel Dis.; 2011; 17, pp. 1971-1978. [DOI: https://dx.doi.org/10.1002/ibd.21606] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21830275]
85. Kostic, A.D.; Chun, E.; Robertson, L.; Glickman, J.N.; Gallini, C.A.; Michaud, M.; Clancy, T.E.; Chung, D.C.; Lochhead, P.; Hold, G.L.
86. Castellarin, M.; Warren, R.L.; Freeman, J.D.; Dreolini, L.; Krzywinski, M.; Strauss, J.; Barnes, R.; Watson, P.; Allen-Vercoe, E.; Moore, R.A.
87. Kitamoto, S.; Kamada, N. The oral-gut axis: A missing piece in the IBD puzzle. Inflamm. Regen.; 2023; 43, 54. [DOI: https://dx.doi.org/10.1186/s41232-023-00304-3]
88. Yang, M.; Gu, Y.; Li, L.; Liu, T.; Song, X.; Sun, Y.; Cao, X.; Wang, B.; Jiang, K.; Cao, H. Bile Acid-Gut Microbiota Axis in Inflammatory Bowel Disease: From Bench to Bedside. Nutrients; 2021; 13, 3143. [DOI: https://dx.doi.org/10.3390/nu13093143]
89. Almeida, V.d.S.M.; Azevedo, J.; Leal, H.F.; Queiroz, A.T.L.d.; Filho, H.P.d.S.; Reis, J.N. Bacterial diversity and prevalence of antibiotic resistance genes in the oral microbiome. PLoS ONE; 2020; 15, e0239664. [DOI: https://dx.doi.org/10.1371/journal.pone.0239664]
90. Ahmadi, H.; Ebrahimi, A.; Ahmadi, F. Antibiotic Therapy in Dentistry. Int. J. Dent.; 2021; 2021, 6667624. [DOI: https://dx.doi.org/10.1155/2021/6667624]
91. Antibiotic Prophylaxis. Available online: https://www.ada.org/resources/ada-library/oral-health-topics/antibiotic-prophylaxis (accessed on 20 February 2025).
92. Wilson, W.R.; Gewitz, M.; Lockhart, P.B.; Bolger, A.F.; DeSimone, D.C.; Kazi, D.S.; Couper, D.J.; Beaton, A.; Kilmartin, C.; Miro, J.M.
93. Naghavi, M.; Vollset, S.E.; Ikuta, K.S.; Swetschinski, L.R.; Gray, A.P.; Wool, E.E.; Aguilar, G.R.; Mestrovic, T.; Smith, G.; Han, C.
94. Surveillance of Antimicrobial Resistance in Europe, 2023 Data—Executive Summary. Available online: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2023-data-executive-summary (accessed on 21 February 2025).
95. Lockhart, P.B.; Tampi, M.P.; Abt, E.; Aminoshariae, A.; Durkin, M.J.; Fouad, A.F.; Gopal, P.; Hatten, B.W.; Kennedy, E.; Lang, M.S.
96. Éliás, A.J.; Barna, V.; Patoni, C.; Demeter, D.; Veres, D.S.; Bunduc, S.; Erőss, B.; Hegyi, P.; Földvári-Nagy, L.; Lenti, K. Probiotic supplementation during antibiotic treatment is unjustified in maintaining the gut microbiome diversity: A systematic review and meta-analysis. BMC Med.; 2023; 21, 262. [DOI: https://dx.doi.org/10.1186/s12916-023-02961-0]
97. Szajewska, H.; Scott, K.P.; de Meij, T.; Forslund-Startceva, S.K.; Knight, R.; Koren, O.; Little, P.; Johnston, B.C.; Łukasik, J.; Suez, J.
98. Shaffer, M.; Lozupone, C. Prevalence and Source of Fecal and Oral Bacteria on Infant, Child, and Adult Hands. mSystems; 2018; 3, e00192-17. [DOI: https://dx.doi.org/10.1128/msystems.00192-17] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29359197]
99. Schuurhuis, J.M.; Stokman, M.A.; Witjes, M.J.H.; Langendijk, J.A.; van Winkelhoff, A.J.; Vissink, A.; Spijkervet, F.K.L. Head and neck intensity modulated radiation therapy leads to an increase of opportunistic oral pathogens. Oral Oncol.; 2016; 58, pp. 32-40. [DOI: https://dx.doi.org/10.1016/j.oraloncology.2016.05.005] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27311400]
100. Gaetti-Jardim, E.; Jardim, E.C.G.; Schweitzer, C.M.; da Silva, J.C.L.; Oliveira, M.M.; Masocatto, D.C.; Dos Santos, C.M. Supragingival and subgingival microbiota from patients with poor oral hygiene submitted to radiotherapy for head and neck cancer treatment. Arch. Oral Biol.; 2018; 90, pp. 45-52. [DOI: https://dx.doi.org/10.1016/j.archoralbio.2018.01.003]
101. Kotwal, G.; Cannon, J.L. Environmental persistence and transfer of enteric viruses. Curr. Opin. Virol.; 2014; 4, pp. 37-43. [DOI: https://dx.doi.org/10.1016/j.coviro.2013.12.003]
102. Tahaei, S.M.E.; Mohebbi, S.R.; Zali, M.R. Enteric hepatitis viruses. Gastroenterol. Hepatol. Bed Bench; 2012; 5, pp. 7-15.
103. Wu, J.; Huang, F.; Ling, Z.; Liu, S.; Liu, J.; Fan, J.; Yu, J.; Wang, W.; Jin, X.; Meng, Y.
104. Karst, S.M. The influence of commensal bacteria on infection with enteric viruses. Nat. Rev. Microbiol.; 2016; 14, pp. 197-204. [DOI: https://dx.doi.org/10.1038/nrmicro.2015.25]
105. De Schryver, A.; Van Winckel, M.; Cornelis, K.; Moens, G.; Devlies, G.; De Backer, G. Helicobacter pylori infection: Further evidence for the role of feco-oral transmission. Helicobacter; 2006; 11, pp. 523-528. [DOI: https://dx.doi.org/10.1111/j.1523-5378.2006.00454.x]
106. Leonov, G.E.; Varaeva, Y.R.; Livantsova, E.N.; Starodubova, A.V. The Complicated Relationship of Short-Chain Fatty Acids and Oral Microbiome: A Narrative Review. Biomedicines; 2023; 11, 2749. [DOI: https://dx.doi.org/10.3390/biomedicines11102749]
107. Kim, K.N.; Yao, Y.; Ju, S.Y. Short Chain Fatty Acids and Fecal Microbiota Abundance in Humans with Obesity: A Systematic Review and Meta-Analysis. Nutrients; 2019; 11, 2512. [DOI: https://dx.doi.org/10.3390/nu11102512] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31635264]
108. Wu, J.-T.; Sun, C.-L.; Lai, T.-T.; Liou, C.-W.; Lin, Y.-Y.; Xue, J.-Y.; Wang, H.-W.; Chai, L.M.X.; Lee, Y.-J.; Chen, S.-L.
109. Guan, X.; Li, W.; Meng, H. A double-edged sword: Role of butyrate in the oral cavity and the gut. Mol. Oral Microbiol.; 2021; 36, pp. 121-131. [DOI: https://dx.doi.org/10.1111/omi.12322] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33155411]
110. Asai, S.; Nakamura, Y.; Yamamura, M.; Ikezawa, H.; Namikawa, I. Quantitative analysis of the Epstein-Barr virus-inducing properties of short-chain fatty acids present in the culture fluids of oral bacteria. Arch. Virol.; 1991; 119, pp. 291-296. [DOI: https://dx.doi.org/10.1007/BF01310678]
111. Zheng, X.; He, J.; Wang, L.; Zhou, S.; Peng, X.; Huang, S.; Zheng, L.; Cheng, L.; Hao, Y.; Li, J.
112. Tsuda, H.; Ochiai, K.; Suzuki, N.; Otsuka, K. Butyrate, a bacterial metabolite, induces apoptosis and autophagic cell death in gingival epithelial cells. J. Periodontal Res.; 2010; 45, pp. 626-634. [DOI: https://dx.doi.org/10.1111/j.1600-0765.2010.01277.x]
113. Shoer, S.; Shilo, S.; Godneva, A.; Ben-Yacov, O.; Rein, M.; Wolf, B.C.; Lotan-Pompan, M.; Bar, N.; Weiss, E.I.; Houri-Haddad, Y.
114. Mayorga-Ramos, A.; Barba-Ostria, C.; Simancas-Racines, D.; Guamán, L.P. Protective role of butyrate in obesity and diabetes: New insights. Front. Nutr.; 2022; 9, 1067647. [DOI: https://dx.doi.org/10.3389/fnut.2022.1067647]
115. Ji, Y.; Yin, Y.; Li, Z.; Zhang, W. Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients; 2019; 11, 1712. [DOI: https://dx.doi.org/10.3390/nu11081712]
116. Qin, J.; Li, Y.; Cai, Z.; Li, S.; Zhu, J.; Zhang, F.; Liang, S.; Zhang, W.; Guan, Y.; Shen, D.
117. Schwiertz, A.; Taras, D.; Schäfer, K.; Beijer, S.; Bos, N.A.; Donus, C.; Hardt, P.D. Microbiota and SCFA in lean and overweight healthy subjects. Obesity; 2010; 18, pp. 190-195. [DOI: https://dx.doi.org/10.1038/oby.2009.167] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19498350]
118. Nandy, D.; Craig, S.J.C.; Cai, J.; Tian, Y.; Paul, I.M.; Savage, J.S.; Marini, M.E.; Hohman, E.E.; Reimherr, M.L.; Patterson, A.D.
119. Patil, D.P.; Dhotre, D.P.; Chavan, S.G.; Sultan, A.; Jain, D.S.; Lanjekar, V.B.; Gangawani, J.; Shah, P.S.; Todkar, J.S.; Shah, S.
120. Peng, K.; Dong, W.; Luo, T.; Tang, H.; Zhu, W.; Huang, Y.; Yang, X. Butyrate and obesity: Current research status and future prospect. Front. Endocrinol.; 2023; 14, 1098881. [DOI: https://dx.doi.org/10.3389/fendo.2023.1098881]
121. Gao, Z.; Yin, J.; Zhang, J.; Ward, R.E.; Martin, R.J.; Lefevre, M.; Cefalu, W.T.; Ye, J. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes; 2009; 58, pp. 1509-1517. [DOI: https://dx.doi.org/10.2337/db08-1637]
122. Arora, T.; Tremaroli, V. Therapeutic Potential of Butyrate for Treatment of Type 2 Diabetes. Front. Endocrinol.; 2021; 12, 761834. [DOI: https://dx.doi.org/10.3389/fendo.2021.761834]
123. Li, X.; He, M.; Yi, X.; Lu, X.; Zhu, M.; Xue, M.; Tang, Y.; Zhu, Y. Short-chain fatty acids in nonalcoholic fatty liver disease: New prospects for short-chain fatty acids as therapeutic targets. Heliyon; 2024; 10, e26991. [DOI: https://dx.doi.org/10.1016/j.heliyon.2024.e26991]
124. Canfora, E.E.; Jocken, J.W.; Blaak, E.E. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat. Rev. Endocrinol.; 2015; 11, pp. 577-591. [DOI: https://dx.doi.org/10.1038/nrendo.2015.128]
125. Pant, K.; Venugopal, S.K.; Lorenzo Pisarello, M.J.; Gradilone, S.A. The Role of Gut Microbiome-Derived Short-Chain Fatty Acid Butyrate in Hepatobiliary Diseases. Am. J. Pathol.; 2023; 193, pp. 1455-1467. [DOI: https://dx.doi.org/10.1016/j.ajpath.2023.06.007] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/37422149]
126. Ren, Y.; Chen, M.; Wang, Z.; Han, J.-D.J. Oral microbiota in aging and diseases. Life Med.; 2024; 3, lnae024. [DOI: https://dx.doi.org/10.1093/lifemedi/lnae024] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/39871894]
127. Guo, X.; Shao, Y. Role of the oral-gut microbiota axis in pancreatic cancer: A new perspective on tumor pathophysiology, diagnosis, and treatment. Mol. Med.; 2025; 31, 103. [DOI: https://dx.doi.org/10.1186/s10020-025-01166-w] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/40102723]
128. Adil, N.A.; Omo-Erigbe, C.; Yadav, H.; Jain, S. The Oral–Gut Microbiome–Brain Axis in Cognition. Microorganisms; 2025; 13, 814. [DOI: https://dx.doi.org/10.3390/microorganisms13040814]
129. Azzolino, D.; Coelho-Junior, H.J.; Proietti, M.; Manzini, V.M.; Cesari, M. Fatigue in older persons: The role of nutrition. Proc. Nutr. Soc.; 2023; 82, pp. 39-46. [DOI: https://dx.doi.org/10.1017/S0029665122002683]
130. Huang, X.; Li, Y.; Zhang, J.; Feng, Q. Linking Periodontitis with Inflammatory Bowel Disease through the Oral–Gut Axis: The Potential Role of Porphyromonas gingivalis. Biomedicines; 2024; 12, 685. [DOI: https://dx.doi.org/10.3390/biomedicines12030685]
131. Qian, J.; Lu, J.; Huang, Y.; Wang, M.; Chen, B.; Bao, J.; Wang, L.; Cui, D.; Luo, B.; Yan, F. Periodontitis Salivary Microbiota Worsens Colitis. J. Dent. Res.; 2022; 101, pp. 559-568. [DOI: https://dx.doi.org/10.1177/00220345211049781]
132. Tanwar, H.; Gnanasekaran, J.M.; Allison, D.; Chuang, L.-S.; He, X.; Aimetti, M.; Baima, G.; Costalonga, M.; Cross, R.K.; Sears, C.
133. Khodaii, Z.; Mehrabani, M.; Rafieian, N.; Najafi-Parizi, G.A.; Mirzaei, A.; Akbarzadeh, R. Altered levels of salivary biochemical markers in periodontitis. Am. J. Dent.; 2019; 32, pp. 183-186.
134. Li, X.; Li, Q.; Wang, L.; Ding, H.; Wang, Y.; Liu, Y.; Gong, T. The interaction between oral microbiota and gut microbiota in atherosclerosis. Front. Cardiovasc. Med.; 2024; 11, 1406220. [DOI: https://dx.doi.org/10.3389/fcvm.2024.1406220]
135. L’Heureux, J.E.; van der Giezen, M.; Winyard, P.G.; Jones, A.M.; Vanhatalo, A. Localisation of nitrate-reducing and highly abundant microbial communities in the oral cavity. PLoS ONE; 2023; 18, e0295058. [DOI: https://dx.doi.org/10.1371/journal.pone.0295058] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/38127919]
136. Lundberg, J.O.; Weitzberg, E.; Gladwin, M.T. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat. Rev. Drug Discov.; 2008; 7, pp. 156-167. [DOI: https://dx.doi.org/10.1038/nrd2466] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18167491]
137. Lundberg, J.O.; Carlström, M.; Larsen, F.J.; Weitzberg, E. Roles of dietary inorganic nitrate in cardiovascular health and disease. Cardiovasc. Res.; 2011; 89, pp. 525-532. [DOI: https://dx.doi.org/10.1093/cvr/cvq325] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20937740]
138. Vanhatalo, A.; Blackwell, J.R.; L’Heureux, J.E.; Williams, D.W.; Smith, A.; van der Giezen, M.; Winyard, P.G.; Kelly, J.; Jones, A.M. Nitrate-responsive oral microbiome modulates nitric oxide homeostasis and blood pressure in humans. Free. Radic. Biol. Med.; 2018; 124, pp. 21-30. [DOI: https://dx.doi.org/10.1016/j.freeradbiomed.2018.05.078]
139. Fennema, D.; Phillips, I.R.; Shephard, E.A. Trimethylamine and Trimethylamine N-Oxide, a Flavin-Containing Monooxygenase 3 (FMO3)-Mediated Host-Microbiome Metabolic Axis Implicated in Health and Disease. Drug Metab. Dispos.; 2016; 44, pp. 1839-1850. [DOI: https://dx.doi.org/10.1124/dmd.116.070615]
140. Barrea, L.; Annunziata, G.; Muscogiuri, G.; Di Somma, C.; Laudisio, D.; Maisto, M.; de Alteriis, G.; Tenore, G.C.; Colao, A.; Savastano, S. Trimethylamine-N-oxide (TMAO) as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome. Nutrients; 2018; 10, 1971. [DOI: https://dx.doi.org/10.3390/nu10121971]
141. Wang, B.; Qiu, J.; Lian, J.; Yang, X.; Zhou, J. Gut Metabolite Trimethylamine-N-Oxide in Atherosclerosis: From Mechanism to Therapy. Front. Cardiovasc. Med.; 2021; 8, 723886. [DOI: https://dx.doi.org/10.3389/fcvm.2021.723886]
142. Caradonna, E.; Abate, F.; Schiano, E.; Paparella, F.; Ferrara, F.; Vanoli, E.; Difruscolo, R.; Goffredo, V.M.; Amato, B.; Setacci, C.
143. Zhou, S.; Xue, J.; Shan, J.; Hong, Y.; Zhu, W.; Nie, Z.; Zhang, Y.; Ji, N.; Luo, X.; Zhang, T.
144. He, Z.; Kwek, E.; Hao, W.; Zhu, H.; Liu, J.; Ma, K.Y.; Chen, Z.-Y. Hawthorn fruit extract reduced trimethylamine-N-oxide (TMAO)-exacerbated atherogenesis in mice via anti-inflammation and anti-oxidation. Nutr. Metab.; 2021; 18, 6. [DOI: https://dx.doi.org/10.1186/s12986-020-00535-y]
145. Jiang, S.; Shui, Y.; Cui, Y.; Tang, C.; Wang, X.; Qiu, X.; Hu, W.; Fei, L.; Li, Y.; Zhang, S.
146. Scannapieco, F.A.; Cantos, A. Oral inflammation and infection, and chronic medical diseases: Implications for the elderly. Periodontol. 2000; 2016; 72, pp. 153-175. [DOI: https://dx.doi.org/10.1111/prd.12129] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27501498]
147. Sun, R.; Xu, C.; Feng, B.; Gao, X.; Liu, Z. Critical roles of bile acids in regulating intestinal mucosal immune responses. Ther. Adv. Gastroenterol.; 2021; 14, 17562848211018098. [DOI: https://dx.doi.org/10.1177/17562848211018098] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34104213]
148. Dosedělová, V.; Laštovičková, M.; Ayala-Cabrera, J.F.; Dolina, J.; Konečný, Š.; Schmitz, O.J.; Kubáň, P. Quantification and identification of bile acids in saliva by liquid chromatography-mass spectrometry: Possible non-invasive diagnostics of Barrett’s esophagus?. J. Chromatogr. A; 2022; 1676, 463287. [DOI: https://dx.doi.org/10.1016/j.chroma.2022.463287]
149. Ma, K.; Saha, P.K.; Chan, L.; Moore, D.D. Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Investig.; 2006; 116, pp. 1102-1109. [DOI: https://dx.doi.org/10.1172/JCI25604]
150. Taoka, H.; Yokoyama, Y.; Morimoto, K.; Kitamura, N.; Tanigaki, T.; Takashina, Y.; Tsubota, K.; Watanabe, M. Role of bile acids in the regulation of the metabolic pathways. World J. Diabetes; 2016; 7, pp. 260-270. [DOI: https://dx.doi.org/10.4239/wjd.v7.i13.260]
151. Yang, Z.-X.; Shen, W.; Sun, H. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatol. Int.; 2010; 4, pp. 741-748. [DOI: https://dx.doi.org/10.1007/s12072-010-9202-6]
152. Zhang, L.; Xie, C.; Nichols, R.G.; Chan, S.H.J.; Jiang, C.; Hao, R.; Smith, P.B.; Cai, J.; Simons, M.N.; Hatzakis, E.
153. Cariou, B.; Duran-Sandoval, D.; Kuipers, F.; Staels, B. Farnesoid X Receptor: A New Player in Glucose Metabolism?. Endocrinology; 2005; 146, pp. 981-983. [DOI: https://dx.doi.org/10.1210/en.2004-1595]
154. Thomas, C.; Gioiello, A.; Noriega, L.; Strehle, A.; Oury, J.; Rizzo, G.; Macchiarulo, A.; Yamamoto, H.; Mataki, C.; Pruzanski, M.
155. Lou, G.; Ma, X.; Fu, X.; Meng, Z.; Zhang, W.; Wang, Y.-D.; Ness, C.V.; Yu, D.; Xu, R.; Huang, W. GPBAR1/TGR5 Mediates Bile Acid-Induced Cytokine Expression in Murine Kupffer Cells. PLoS ONE; 2014; 9, e93567. [DOI: https://dx.doi.org/10.1371/journal.pone.0093567] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24755711]
156. Cheung, K.C.P.; Ma, J.; Loiola, R.A.; Chen, X.; Jia, W. Bile acid-activated receptors in innate and adaptive immunity: Targeted drugs and biological agents. Eur. J. Immunol.; 2023; 53, 2250299. [DOI: https://dx.doi.org/10.1002/eji.202250299] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/37172599]
157. Bernstein, H.; Bernstein, C. Bile acids as carcinogens in the colon and at other sites in the gastrointestinal system. Exp. Biol. Med.; 2023; 248, pp. 79-89. [DOI: https://dx.doi.org/10.1177/15353702221131858] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36408538]
158. Vakil, N.; van Zanten, S.V.; Kahrilas, P.; Dent, J.; Jones, R. Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus. Am. J. Gastroenterol.; 2006; 101,
159. Nehra, D.; Howell, P.; Williams, C.P.; Pye, J.K.; Beynon, J. Toxic bile acids in gastro-oesophageal reflux disease: Influence of gastric acidity. Gut; 1999; 44, pp. 598-602. [DOI: https://dx.doi.org/10.1136/gut.44.5.598]
160. Kauer, W.K.H.; Peters, J.H.; DeMeester, T.R.; Feussner, H.; Ireland, A.P.; Stein, H.J.; Siewert, R.J. Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. Surgery; 1997; 122, pp. 874-881. [DOI: https://dx.doi.org/10.1016/S0039-6060(97)90327-5]
161. Milani, D.C.; Borba, M.; Farré, R.; Grando, L.G.R.; Bertol, C.; Fornari, F. Gastroesophageal reflux disease and dental erosion: The role of bile acids. Arch. Oral Biol.; 2022; 139, 105429. [DOI: https://dx.doi.org/10.1016/j.archoralbio.2022.105429]
162. Larabi, A.B.; Masson, H.L.P.; Bäumler, A.J. Bile acids as modulators of gut microbiota composition and function. Gut Microbes; 2023; 15, 2172671. [DOI: https://dx.doi.org/10.1080/19490976.2023.2172671]
163. Wahlström, A.; Sayin, S.I.; Marschall, H.-U.; Bäckhed, F. Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. Cell Metab.; 2016; 24, pp. 41-50. [DOI: https://dx.doi.org/10.1016/j.cmet.2016.05.005]
164. Shansky, Y.; Bespyatykh, J. Bile Acids: Physiological Activity and Perspectives of Using in Clinical and Laboratory Diagnostics. Molecules; 2022; 27, 7830. [DOI: https://dx.doi.org/10.3390/molecules27227830]
165. Ocvirk, S.; O’Keefe, S.J.D. Dietary fat, bile acid metabolism and colorectal cancer. Semin. Cancer Biol.; 2021; 73, pp. 347-355. [DOI: https://dx.doi.org/10.1016/j.semcancer.2020.10.003]
166. Guzior, D.V.; Quinn, R.A. Review: Microbial transformations of human bile acids. Microbiome; 2021; 9, 140. [DOI: https://dx.doi.org/10.1186/s40168-021-01101-1]
167. Krause, A.J.; Greytak, M.; Kessler, M.; Yadlapati, R. Pilot study evaluating salivary bile acids as a diagnostic biomarker of laryngopharyngeal reflux. Dis. Esophagus; 2024; 37, doae021. [DOI: https://dx.doi.org/10.1093/dote/doae021]
168. Vageli, D.P.; Doukas, S.G.; Doukas, P.G.; Judson, B.L. Bile reflux and hypopharyngeal cancer (Review). Oncol. Rep.; 2021; 46, 244. [DOI: https://dx.doi.org/10.3892/or.2021.8195]
169. Cleaver, L.M.; Carda-Diéguez, M.; Moazzez, R.; Carpenter, G.H. Novel bacterial proteolytic and metabolic activity associated with dental erosion-induced oral dysbiosis. Microbiome; 2023; 11, 69. [DOI: https://dx.doi.org/10.1186/s40168-023-01514-0]
170. Boisen, G.; Davies, J.R.; Neilands, J. Acid tolerance in early colonizers of oral biofilms. BMC Microbiol.; 2021; 21, 45. [DOI: https://dx.doi.org/10.1186/s12866-021-02089-2]
171. Dipalma, G.; Inchingolo, A.D.; Inchingolo, F.; Charitos, I.A.; Di Cosola, M.; Cazzolla, A.P. Focus on the cariogenic process: Microbial and biochemical interactions with teeth and oral environment. J. Biol. Regul. Homeost. Agents; 2021; 35, pp. 429-440. [DOI: https://dx.doi.org/10.23812/20-747-A]
172. Liu, R.; Liu, Y.; Yi, J.; Fang, Y.; Guo, Q.; Cheng, L.; He, J.; Li, M. Imbalance of oral microbiome homeostasis: The relationship between microbiota and the occurrence of dental caries. BMC Microbiol.; 2025; 25, 46. [DOI: https://dx.doi.org/10.1186/s12866-025-03762-6]
173. Zhu, J.; Chu, W.; Luo, J.; Yang, J.; He, L.; Li, J. Dental Materials for Oral Microbiota Dysbiosis: An Update. Front. Cell. Infect. Microbiol.; 2022; 12, 900918. [DOI: https://dx.doi.org/10.3389/fcimb.2022.900918]
174. Kawar, N.; Park, S.G.; Schwartz, J.L.; Callahan, N.; Obrez, A.; Yang, B.; Chen, Z.; Adami, G.R. Salivary microbiome with gastroesophageal reflux disease and treatment. Sci. Rep.; 2021; 11, 188. [DOI: https://dx.doi.org/10.1038/s41598-020-80170-y]
175. Zhang, Z.; Curran, G.; Altinok Dindar, D.; Wu, Y.; Wu, H.; Sharpton, T.; Zhao, L.; Lieberman, D.; Otaki, F. Insights into the Oral Microbiome and Barrett’s Esophagus Early Detection: A Narrative Review. Clin. Transl. Gastroenterol.; 2021; 12, e00390. [DOI: https://dx.doi.org/10.14309/ctg.0000000000000390]
176. Liu, S.; Wang, S.; Zhang, N.; Li, P. The oral microbiome and oral and upper gastrointestinal diseases. J. Oral Microbiol.; 2024; 16, 2355823. [DOI: https://dx.doi.org/10.1080/20002297.2024.2355823]
177. Snider, E.J.; Freedberg, D.E.; Abrams, J.A. Potential Role of the Microbiome in Barrett’s Esophagus and Esophageal Adenocarcinoma. Dig. Dis. Sci.; 2016; 61, pp. 2217-2225. [DOI: https://dx.doi.org/10.1007/s10620-016-4155-9]
178. Grigor’eva, I.N.; Romanova, T.I. Gallstone Disease and Microbiome. Microorganisms; 2020; 8, 835. [DOI: https://dx.doi.org/10.3390/microorganisms8060835]
179. Ye, F.; Shen, H.; Li, Z.; Meng, F.; Li, L.; Yang, J.; Chen, Y.; Bo, X.; Zhang, X.; Ni, M. Influence of the Biliary System on Biliary Bacteria Revealed by Bacterial Communities of the Human Biliary and Upper Digestive Tracts. PLoS ONE; 2016; 11, e0150519. [DOI: https://dx.doi.org/10.1371/journal.pone.0150519]
180. Bhandari, S.; Reddy, M.; Shahzad, G. Association between oral hygiene and ultrasound-confirmed gallstone disease in US population. Eur. J. Gastroenterol. Hepatol.; 2017; 29, pp. 861-862. [DOI: https://dx.doi.org/10.1097/MEG.0000000000000885]
181. Melander, R.J.; Minvielle, M.J.; Melander, C. Controlling bacterial behavior with indole-containing natural products and derivatives. Tetrahedron; 2014; 70, pp. 6363-6372. [DOI: https://dx.doi.org/10.1016/j.tet.2014.05.089]
182. Ding, J.; Tan, L.; Wu, L.; Li, J.; Zhang, Y.; Shen, Z.; Zhang, C.; Zhao, C.; Gao, L. Regulation of tryptophan-indole metabolic pathway in Porphyromonas gingivalis virulence and microbiota dysbiosis in periodontitis. npj Biofilms Microbiomes; 2025; 11, 37. [DOI: https://dx.doi.org/10.1038/s41522-025-00669-y]
183. Lee, J.-H.; Lee, J. Indole as an intercellular signal in microbial communities. FEMS Microbiol. Rev.; 2010; 34, pp. 426-444. [DOI: https://dx.doi.org/10.1111/j.1574-6976.2009.00204.x]
184. Li, X.; Zhang, B.; Hu, Y.; Zhao, Y. New Insights into Gut-Bacteria-Derived Indole and Its Derivatives in Intestinal and Liver Diseases. Front. Pharmacol.; 2021; 12, 769501. [DOI: https://dx.doi.org/10.3389/fphar.2021.769501]
185. Kumar, P.; Lee, J.-H.; Lee, J. Diverse roles of microbial indole compounds in eukaryotic systems. Biol. Rev.; 2021; 96, pp. 2522-2545. [DOI: https://dx.doi.org/10.1111/brv.12765]
186. Chimerel, C.; Emery, E.; Summers, D.K.; Keyser, U.; Gribble, F.M.; Reimann, F. Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells. Cell Rep.; 2014; 9, pp. 1202-1208. [DOI: https://dx.doi.org/10.1016/j.celrep.2014.10.032]
187. Zelante, T.; Iannitti, R.G.; Cunha, C.; De Luca, A.; Giovannini, G.; Pieraccini, G.; Zecchi, R.; D’Angelo, C.; Massi-Benedetti, C.; Fallarino, F.
188. Alexeev, E.E.; Lanis, J.M.; Kao, D.J.; Campbell, E.L.; Kelly, C.J.; Battista, K.D.; Gerich, M.E.; Jenkins, B.R.; Walk, S.T.; Kominsky, D.J.
189. Natividad, J.M.; Agus, A.; Planchais, J.; Lamas, B.; Jarry, A.C.; Martin, R.; Michel, M.-L.; Chong-Nguyen, C.; Roussel, R.; Straube, M.
190. Krishnan, S.; Ding, Y.; Saedi, N.; Choi, M.; Sridharan, G.V.; Sherr, D.H.; Yarmush, M.L.; Alaniz, R.C.; Jayaraman, A.; Lee, K. Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages. Cell Rep.; 2018; 23, pp. 1099-1111. [DOI: https://dx.doi.org/10.1016/j.celrep.2018.03.109]
191. Venkatesh, M.; Mukherjee, S.; Wang, H.; Li, H.; Sun, K.; Benechet, A.P.; Qiu, Z.; Maher, L.; Redinbo, M.R.; Phillips, R.S.
192. Abildgaard, A.; Elfving, B.; Hokland, M.; Wegener, G.; Lund, S. The microbial metabolite indole-3-propionic acid improves glucose metabolism in rats, but does not affect behaviour. Arch. Physiol. Biochem.; 2018; 124, pp. 306-312. [DOI: https://dx.doi.org/10.1080/13813455.2017.1398262]
193. Zhao, Z.Z.; Shan, W.; Guo, L.; Chu, C.H.; Zhang, J. Quorum sensing in Porphyromonas gingivalis and oral microbial interactions: A scoping review. Front. Oral Health; 2025; 6, 1573863. [DOI: https://dx.doi.org/10.3389/froh.2025.1573863]
194. Guo, L.; He, X.; Shi, W. Intercellular communications in multispecies oral microbial communities. Front. Microbiol.; 2014; 5, 328. [DOI: https://dx.doi.org/10.3389/fmicb.2014.00328]
195. Rickard, A.H.; Palmer, R.J.; Blehert, D.S.; Campagna, S.R.; Semmelhack, M.F.; Egland, P.G.; Bassler, B.L.; Kolenbrander, P.E. Autoinducer 2: A concentration-dependent signal for mutualistic bacterial biofilm growth. Mol. Microbiol.; 2006; 60, pp. 1446-1456. [DOI: https://dx.doi.org/10.1111/j.1365-2958.2006.05202.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16796680]
196. Scardina, G.A.; Messina, P. Good Oral Health and Diet. BioMed Res. Int.; 2012; 2012, 720692. [DOI: https://dx.doi.org/10.1155/2012/720692] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22363174]
197. Azzolino, D.; Felicetti, A.; Santacroce, L.; Lucchi, T.; Garcia-Godoy, F.; Passarelli, P.C. The emerging role of oral microbiota: A key driver of oral and systemic health. Am. J. Dent.; 2025; 38, pp. 111-116. [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/40455948]
198. de Vrese, M.; Schrezenmeir, J. Probiotics, prebiotics, and synbiotics. Food Biotechnology; Springer: Berlin/Heidelberg, Germany, 2008; Volume 111, pp. 1-66. [DOI: https://dx.doi.org/10.1007/10_2008_097]
199. Ticinesi, A.; Lauretani, F.; Milani, C.; Nouvenne, A.; Tana, C.; Del Rio, D.; Maggio, M.; Ventura, M.; Meschi, T. Aging Gut Microbiota at the Cross-Road between Nutrition, Physical Frailty, and Sarcopenia: Is There a Gut–Muscle Axis?. Nutrients; 2017; 9, 1303. [DOI: https://dx.doi.org/10.3390/nu9121303]
200. Jurtshuk, P. Bacterial Metabolism. Medical Microbiology; 4th ed. Baron, S. University of Texas Medical Branch at Galveston: Galveston, TX, USA, 1996; ISBN 978-0-9631172-1-2
201. Wade, W.G. The oral microbiome in health and disease. Pharmacol. Res.; 2013; 69, pp. 137-143. [DOI: https://dx.doi.org/10.1016/j.phrs.2012.11.006]
202. Bowden, G.H.; Li, Y.H. Nutritional influences on biofilm development. Adv. Dent. Res.; 1997; 11, pp. 81-99. [DOI: https://dx.doi.org/10.1177/08959374970110012101]
203. Furman, D.; Campisi, J.; Verdin, E.; Carrera-Bastos, P.; Targ, S.; Franceschi, C.; Ferrucci, L.; Gilroy, D.W.; Fasano, A.; Miller, G.W.
204. Millen, A.E.; Dahhan, R.; Freudenheim, J.L.; Hovey, K.M.; Li, L.; McSkimming, D.I.; Andrews, C.A.; Buck, M.J.; LaMonte, M.J.; Kirkwood, K.L.
205. Kondo, K.; Ishikado, A.; Morino, K.; Nishio, Y.; Ugi, S.; Kajiwara, S.; Kurihara, M.; Iwakawa, H.; Nakao, K.; Uesaki, S.
206. Altun, E.; Walther, C.; Borof, K.; Petersen, E.; Lieske, B.; Kasapoudis, D.; Jalilvand, N.; Beikler, T.; Jagemann, B.; Zyriax, B.-C.
207. Dagli, N.; Dagli, R.; Darwish, S.; Baroudi, K. Oral Microbial Shift: Factors affecting the Microbiome and Prevention of Oral Disease. J. Contemp. Dent. Pract.; 2016; 17, pp. 90-96. [DOI: https://dx.doi.org/10.5005/jp-journals-10024-1808]
208. Chen, T.; Yu, W.-H.; Izard, J.; Baranova, O.V.; Lakshmanan, A.; Dewhirst, F.E. The Human Oral Microbiome Database: A web accessible resource for investigating oral microbe taxonomic and genomic information. Database; 2010; 2010, baq013. [DOI: https://dx.doi.org/10.1093/database/baq013]
209. Samaranayake, L.; Matsubara, V.H. Normal Oral Flora and the Oral Ecosystem. Dent. Clin. N. Am.; 2017; 61, pp. 199-215. [DOI: https://dx.doi.org/10.1016/j.cden.2016.11.002]
210. Hansen, T.H.; Kern, T.; Bak, E.G.; Kashani, A.; Allin, K.H.; Nielsen, T.; Hansen, T.; Pedersen, O. Impact of a vegan diet on the human salivary microbiota. Sci. Rep.; 2018; 8, 5847. [DOI: https://dx.doi.org/10.1038/s41598-018-24207-3] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29643500]
211. Meyer, A.; Agrawal, M.; Savin-Shalom, E.; Wong, E.C.L.; Levinson, C.; Gold, S.; Narula, N.; Colombel, J.-F.; Carbonnel, F. Impact of diet on inflammatory bowel disease risk: Systematic review, meta-analyses and implications for prevention. eClinicalMedicine; 2025; 86, 103353. [DOI: https://dx.doi.org/10.1016/j.eclinm.2025.103353] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/40697960]
212. Cronin, P.; Joyce, S.A.; O’Toole, P.W.; O’Connor, E.M. Dietary Fibre Modulates the Gut Microbiota. Nutrients; 2021; 13, 1655. [DOI: https://dx.doi.org/10.3390/nu13051655]
213. Malesza, I.J.; Malesza, M.; Walkowiak, J.; Mussin, N.; Walkowiak, D.; Aringazina, R.; Bartkowiak-Wieczorek, J.; Mądry, E. High-Fat, Western-Style Diet, Systemic Inflammation, and Gut Microbiota: A Narrative Review. Cells; 2021; 10, 3164. [DOI: https://dx.doi.org/10.3390/cells10113164]
214. Kinashi, Y.; Hase, K. Partners in Leaky Gut Syndrome: Intestinal Dysbiosis and Autoimmunity. Front. Immunol.; 2021; 12, 673708. [DOI: https://dx.doi.org/10.3389/fimmu.2021.673708]
215. Sato, S.; Chinda, D.; Iino, C.; Sawada, K.; Mikami, T.; Nakaji, S.; Sakuraba, H.; Fukuda, S. A Cohort Study of the Influence of the 12-Component Modified Japanese Diet Index on Oral and Gut Microbiota in the Japanese General Population. Nutrients; 2024; 16, 524. [DOI: https://dx.doi.org/10.3390/nu16040524]
216. Eremenko, M.; Pink, C.; Biffar, R.; Schmidt, C.O.; Ittermann, T.; Kocher, T.; Meisel, P. Cross-sectional association between physical strength, obesity, periodontitis and number of teeth in a general population. J. Clin. Periodontol.; 2016; 43, pp. 401-407. [DOI: https://dx.doi.org/10.1111/jcpe.12531]
217. Santonocito, S.; Giudice, A.; Polizzi, A.; Troiano, G.; Merlo, E.M.; Sclafani, R.; Grosso, G.; Isola, G. A Cross-Talk between Diet and the Oral Microbiome: Balance of Nutrition on Inflammation and Immune System’s Response during Periodontitis. Nutrients; 2022; 14, 2426. [DOI: https://dx.doi.org/10.3390/nu14122426]
218. Seidel, D.V.; Azcárate-Peril, M.A.; Chapkin, R.S.; Turner, N.D. Shaping functional gut microbiota using dietary bioactives to reduce colon cancer risk. Semin. Cancer Biol.; 2017; 46, pp. 191-204. [DOI: https://dx.doi.org/10.1016/j.semcancer.2017.06.009] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28676459]
219. Riboli, E.; Norat, T. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am. J. Clin. Nutr.; 2003; 78, pp. 559S-569S. [DOI: https://dx.doi.org/10.1093/ajcn/78.3.559S] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12936950]
220. Terry, P.; Giovannucci, E.; Michels, K.B.; Bergkvist, L.; Hansen, H.; Holmberg, L.; Wolk, A. Fruit, vegetables, dietary fiber, and risk of colorectal cancer. J. Natl. Cancer Inst.; 2001; 93, pp. 525-533. [DOI: https://dx.doi.org/10.1093/jnci/93.7.525] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11287446]
221. Trock, B.; Lanza, E.; Greenwald, P. Dietary fiber, vegetables, and colon cancer: Critical review and meta-analyses of the epidemiologic evidence. J. Natl. Cancer Inst.; 1990; 82, pp. 650-661. [DOI: https://dx.doi.org/10.1093/jnci/82.8.650]
222. Kris-Etherton, P.M.; Hecker, K.D.; Bonanome, A.; Coval, S.M.; Binkoski, A.E.; Hilpert, K.F.; Griel, A.E.; Etherton, T.D. Bioactive compounds in foods: Their role in the prevention of cardiovascular disease and cancer. Am. J. Med.; 2002; 113, (Suppl. 9B), pp. 71S-88S. [DOI: https://dx.doi.org/10.1016/S0002-9343(01)00995-0]
223. Mazzola, G.; Cattaneo, C.; Patta, E.; Alalwan, T.A.; Azzolino, D.; Perna, S.; Rondanelli, M. Sustainable Plant-Based Diets and Food Allergies: A Scoping Review Inspired by EAT-Lancet. Appl. Sci.; 2025; 15, 7296. [DOI: https://dx.doi.org/10.3390/app15137296]
224. Azzola, L.G.; Fankhauser, N.; Srinivasan, M. Influence of the vegan, vegetarian and omnivore diet on the oral health status in adults: A systematic review and meta-analysis. Evid. Based Dent.; 2023; 24, pp. 43-44. [DOI: https://dx.doi.org/10.1038/s41432-023-00853-z]
225. Kerstens, R.; Ng, Y.Z.; Pettersson, S.; Jayaraman, A. Balancing the Oral–Gut–Brain Axis with Diet. Nutrients; 2024; 16, 3206. [DOI: https://dx.doi.org/10.3390/nu16183206]
226. Pandya, V.S.; Fiorillo, L.; Kalpe, S.; Mehta, V.; Meto, A.; Certo, A.D.; Russo, D.; Gorassini, F.; Mancini, M.; Mancini, A.
227. Azzolino, D.; Bertoni, C.; De Cosmi, V.; Spolidoro, G.C.I.; Agostoni, C.; Lucchi, T.; Mazzocchi, A. Omega-3 polyunsatured fatty acids and physical performance across the lifespan: A narrative review. Front. Nutr.; 2024; 11, 1414132. [DOI: https://dx.doi.org/10.3389/fnut.2024.1414132]
228. Lee, C.-T.; Tribble, G.D. Roles of specialized pro-resolving mediators and omega-3 polyunsaturated fatty acids in periodontal inflammation and impact on oral microbiota. Front. Oral Health; 2023; 4, 1217088. [DOI: https://dx.doi.org/10.3389/froh.2023.1217088]
229. Awoyemi, A.; Trøseid, M.; Arnesen, H.; Solheim, S.; Seljeflot, I. Effects of dietary intervention and n-3 PUFA supplementation on markers of gut-related inflammation and their association with cardiovascular events in a high-risk population. Atherosclerosis; 2019; 286, pp. 53-59. [DOI: https://dx.doi.org/10.1016/j.atherosclerosis.2019.05.004] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31100620]
230. Huang, C.B.; Ebersole, J.L. A novel bioactivity of omega-3 polyunsaturated fatty acids and their ester derivatives. Mol. Oral Microbiol.; 2010; 25, pp. 75-80. [DOI: https://dx.doi.org/10.1111/j.2041-1014.2009.00553.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20331795]
231. Sun, M.; Zhou, Z.; Dong, J.; Zhang, J.; Xia, Y.; Shu, R. Antibacterial and antibiofilm activities of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) against periodontopathic bacteria. Microb. Pathog.; 2016; 99, pp. 196-203. [DOI: https://dx.doi.org/10.1016/j.micpath.2016.08.025] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27565090]
232. Stańdo-Retecka, M.; Piatek, P.; Namiecinska, M.; Bonikowski, R.; Lewkowicz, P.; Lewkowicz, N. Clinical and microbiological outcomes of subgingival instrumentation supplemented with high-dose omega-3 polyunsaturated fatty acids in periodontal treatment—A randomized clinical trial. BMC Oral Health; 2023; 23, 290. [DOI: https://dx.doi.org/10.1186/s12903-023-03018-7]
233. Shama, S.; Liu, W. Omega-3 Fatty Acids and Gut Microbiota: A Reciprocal Interaction in Nonalcoholic Fatty Liver Disease. Dig. Dis. Sci.; 2020; 65, pp. 906-910. [DOI: https://dx.doi.org/10.1007/s10620-020-06117-5]
234. Fan, X.; Peters, B.A.; Jacobs, E.J.; Gapstur, S.M.; Purdue, M.P.; Freedman, N.D.; Alekseyenko, A.V.; Wu, J.; Yang, L.; Pei, Z.
235. Hill, C.; Guarner, F.; Reid, G.; Gibson, G.R.; Merenstein, D.J.; Pot, B.; Morelli, L.; Canani, R.B.; Flint, H.J.; Salminen, S.
236. Gibson, G.R.; Hutkins, R.; Sanders, M.E.; Prescott, S.L.; Reimer, R.A.; Salminen, S.J.; Scott, K.; Stanton, C.; Swanson, K.S.; Cani, P.D.
237. Slomka, V.; Herrero, E.R.; Boon, N.; Bernaerts, K.; Trivedi, H.M.; Daep, C.; Quirynen, M.; Teughels, W. Oral prebiotics and the influence of environmental conditions in vitro. J. Periodontol.; 2018; 89, pp. 708-717. [DOI: https://dx.doi.org/10.1002/JPER.17-0437] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29577296]
238. Hemarajata, P.; Versalovic, J. Effects of probiotics on gut microbiota: Mechanisms of intestinal immunomodulation and neuromodulation. Ther. Adv. Gastroenterol.; 2013; 6, pp. 39-51. [DOI: https://dx.doi.org/10.1177/1756283X12459294] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23320049]
239. Santacroce, L.; Charitos, I.A.; Bottalico, L. A successful history: Probiotics and their potential as antimicrobials. Expert Rev. Anti-Infect. Ther.; 2019; 17, pp. 635-645. [DOI: https://dx.doi.org/10.1080/14787210.2019.1645597]
240. Clifford, M.N. Diet-derived phenols in plasma and tissues and their implications for health. Planta Med.; 2004; 70, pp. 1103-1114. [DOI: https://dx.doi.org/10.1055/s-2004-835835]
241. Cueva, C.; Silva, M.; Pinillos, I.; Bartolomé, B.; Moreno-Arribas, M.V. Interplay between Dietary Polyphenols and Oral and Gut Microbiota in the Development of Colorectal Cancer. Nutrients; 2020; 12, 625. [DOI: https://dx.doi.org/10.3390/nu12030625]
242. Kaymaz, K.; Hensel, A.; Beikler, T. Polyphenols in the prevention and treatment of periodontal disease: A systematic review of in vivo, ex vivo and in vitro studies. Fitoterapia; 2019; 132, pp. 30-39. [DOI: https://dx.doi.org/10.1016/j.fitote.2018.11.012]
243. Majewska, M.; Lewandowska, U. The chemopreventive and anticancer potential against colorectal cancer of polyphenol-rich fruit extracts. Food Rev. Int.; 2018; 34, pp. 390-409. [DOI: https://dx.doi.org/10.1080/87559129.2017.1307388]
244. Costea, T.; Hudiță, A.; Ciolac, O.-A.; Gălățeanu, B.; Ginghină, O.; Costache, M.; Ganea, C.; Mocanu, M.-M. Chemoprevention of Colorectal Cancer by Dietary Compounds. Int. J. Mol. Sci.; 2018; 19, 3787. [DOI: https://dx.doi.org/10.3390/ijms19123787]
245. Esteban-Fernández, A.; Zorraquín-Peña, I.; González de Llano, D.; Bartolomé, B.; Moreno-Arribas, M.V. The role of wine and food polyphenols in oral health. Trends Food Sci. Technol.; 2017; 69, pp. 118-130. [DOI: https://dx.doi.org/10.1016/j.tifs.2017.09.008]
246. Palaska, I.; Papathanasiou, E.; Theoharides, T.C. Use of polyphenols in periodontal inflammation. Eur. J. Pharmacol.; 2013; 720, pp. 77-83. [DOI: https://dx.doi.org/10.1016/j.ejphar.2013.10.047]
247. Sánchez, M.C.; Ribeiro-Vidal, H.; Esteban-Fernández, A.; Bartolomé, B.; Figuero, E.; Moreno-Arribas, M.V.; Sanz, M.; Herrera, D. Antimicrobial activity of red wine and oenological extracts against periodontal pathogens in a validated oral biofilm model. BMC Complement Altern. Med.; 2019; 19, 145. [DOI: https://dx.doi.org/10.1186/s12906-019-2533-5]
248. Cano, R.; Bermúdez, V.; Galban, N.; Garrido, B.; Santeliz, R.; Gotera, M.P.; Duran, P.; Boscan, A.; Carbonell-Zabaleta, A.-K.; Durán-Agüero, S.
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
; Carnevale-Schianca Margherita 2
; Santacroce Luigi 3
; Colella Marica 4
; Felicetti Alessia 5
; Terranova Leonardo 2
; Castrejón-Pérez, Roberto Carlos 6
; Garcia-Godoy, Franklin 7
; Lucchi Tiziano 1
; Passarelli, Pier Carmine 8 1 Geriatric Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, 20122 Milan, Italy; [email protected] (D.A.); [email protected] (T.L.)
2 Respiratory Unit, Cystic Fibrosis Adult Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, 20122 Milan, Italy; [email protected] (M.C.-S.); [email protected] (L.T.)
3 Interdisciplinary Department of Medicine, Section of Microbiology and Virology, School of Medicine, University Hospital of Bari, 70124 Bari, Italy; [email protected] (L.S.); [email protected] (M.C.)
4 Interdisciplinary Department of Medicine, Section of Microbiology and Virology, School of Medicine, University Hospital of Bari, 70124 Bari, Italy; [email protected] (L.S.); [email protected] (M.C.), Doctoral School, eCampus University, 22060 Novedrate, Italy
5 Department of Medical and Surgical Sciences, Magna Graecia University, 88100 Catanzaro, Italy; [email protected] (A.F.)
6 Instituto Nacional de Geriatría, National Institutes of Health, Ministry of Health, Ciudad de México 14080, Mexico; [email protected] (R.C.C.-P.)
7 Bioscience Research Center, College of Dentistry, University of Tennessee Health Science Center, Memphis, TN 38163, USA; [email protected] (F.G.-G.), The Forsyth Institute, Cambridge, MA 02142, USA, Department of Surgery, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA
8 Department of Head and Neck and Sensory Organs, Division of Oral Surgery and Implantology, Fondazione Policlinico Universitario A. Gemelli IRCCS, University Cattolica del Sacro Cuore, 00168 Rome, Italy; [email protected] (P.C.P.)